

Rec'd PCT/PTO 13 DEC 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/106616 A2(51) International Patent Classification⁷:

C12N

(21) International Application Number:

PCT/IL03/00501

(22) International Filing Date:

12 June 2003 (12.06.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/388,273

12 June 2002 (12.06.2002) US

(71) Applicant (for all designated States except US): GAVISH-GALILEE BIO APPLICATIONS LTD [IL/IL]; Kibbutz Glil Yam, 46905 Kibbutz Glil Yam (IL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and



(75) Inventors/Applicants (for US only): GROSS, Gideon [IL/IL]; Moshav Almagor, 12 340 M.P. Korazim (IL). MARGALIT, Alon [IL/IL]; Moshav Hossen, 25180 M.P. Western Galilee (IL).

(74) Agent: BEN-AMI, Paulina; Ben-Ami & Associates, P.O. Box 94, Rehovot 76100 (IL).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MEMBRANE-ANCHORED β 2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES

WO 03/106616 A2

(57) Abstract: The invention provides a polynucleotide comprising a sequence encoding a polypeptide comprising a β 2-microglobulin molecule linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β 2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope, wherein said antigenic peptide is not related to an autoimmune disease and is preferably derived from a tumor-associated antigen or from a pathogenic antigen. Antigen presenting cells, and DNA and cellular vaccines for treatment of cancer and infectious diseases, are also provided.

14/12/04

MEMBRANE-ANCHORED β_2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPE

5 FIELD OF THE INVENTION.

The present invention is in the field of Immunology and relates to DNA molecules encoding chimeric polypeptides comprising β_2 -microglobulin and a polypeptide stretch for anchoring the β_2 -microglobulin molecule to the cell membrane, herein referred to as single-chimeric β_2 -microglobulin (sc β_2 m), and to such DNA molecules further comprising at least one antigenic peptide linked to the amino terminal of the β_2 -microglobulin molecule, herein referred to as double-chimeric β_2 -microglobulin (dc β_2 m), wherein the antigenic peptide is not a peptide related to an autoimmune disease, and to antigen-presenting cells expressing said sc β_2 m and dc β_2 m polypeptides, as novel tools for efficient CTL induction for the treatment of cancer and infectious diseases.

ABBREVIATIONS: APC: antigen-presenting cell; β_2 m: β_2 -microglobulin; BCR: B cell receptor; CDR: complementarity-determining region; CTL: cytotoxic T lymphocyte; dc β_2 m: double-chimeric β_2 -microglobulin; DC: dendritic cells; ER: endoplasmic reticulum; GPI: glycosyl-phosphatidylinositol; Ha: hemagglutinin; h β_2 m: human β_2 -microglobulin; HLA: human leukocyte antigen (=human MHC); Ig: immunoglobulin; ITAM: immunoreceptor tyrosine-based activation motif; mAb: monoclonal antibody; m β_2 m: mouse β_2 -microglobulin; MFI: mean fluorescence intensity; MHC: major histocompatibility complex; NP: nucleoprotein; OVA: chicken ovalbumin; RT-PCR: reverse transcriptase-polymerase chain reaction; sc β_2 m: single-chimeric β_2 -microglobulin TAA: tumor associated antigen; TAP: transporter associated with antigen processing; TCR: T-cell receptor; T_H: T helper cells; TRP: tyrosinase-related protein.

BACKGROUND OF THE INVENTION

The discovery, in recent years, of tumor associated antigens (TAAs) in a growing list of primary human tumors has led to the recognition that most, if not all types of human cancers express tumor antigens. The realization that some TAAs 5 can elicit immune responses that lead to tumor rejection, has refueled interest in the field of cancer immunology, raising hopes for the development of potent anticancer immunotherapeutic tools and cancer vaccines (for reviews, see Minev et al., 1999; Gilboa et al., 1998; Rosenberg, 1999).

Tumor antigens can be divided according to the type of immune response 10 they induce: humoral or cellular, which can be further subdivided into CD4⁺ (helper) and CD8⁺ (cytotoxic) T cell responses. Most TAAs known today were identified by their ability to induce cellular responses, predominantly by cytotoxic T lymphocytes (CTLs). CTLs utilize their clonotypic T cell receptor (TCR) to recognize antigenic peptides presented on major histocompatibility complex (MHC) 15 class I molecules, which are expressed by most nucleated cells in the body. These proteins consist of a membrane-attached α heavy chain, which harbors three structurally distinct extracellular domains ($\alpha 1$ - $\alpha 3$), and a non-covalently associated β_2 microglobulin (β_2 m) light chain, that is not anchored to the cell membrane. Peptides, typically 8-10 amino acids long, bind to a special groove formed between 20 the two membrane-distal domains of the α chain, $\alpha 1$ and $\alpha 2$, mainly via 2-3 dominant anchor residues.

CTLs serve as the major effector arm of the immune system and represent an important component of an animal's or an individual's immune response against a variety of pathogens and cancers. CTLs which have been specifically activated 25 against a particular antigen are capable of killing the cell that contains or expresses the antigen. CTLs are particularly important in providing an effective immune response against intracellular pathogens, such as a wide variety of viruses, and some bacteria and parasites, as well as against tumors.

Some tumors down-regulate MHC class I expression, implying a strong 30 selective pressure imposed by CTLs. In addition, CTLs are capable of recognizing

single amino acid substitutions such as those that occur in TAAs resulting from point mutations. All these suggest that TAAs-derived MHC class I peptides are likely to constitute effective rejection antigens.

CTL activation, or priming, requires that antigenic peptides be presented initially on professional antigen-presenting cells (APCs), primarily dendritic cells (DCs), in secondary lymphoid organs (Steinman, 1989). In addition to highly efficient antigen presentation, DCs provide a co-stimulatory signal, which is mandatory for T cell priming, usually by engagement of their up-regulated B7 molecules with their CD28 receptor on the T cell (Janeway and Bottomly, 1994). Acquisition of the ability of the DC to prime CTLs is primarily mediated by antigen-specific CD4 T cells in a process referred to as 'licensing'. It involves interaction of the TCR of the CD4 T cell with an antigenic peptide on an MHC class II molecule on the DC and concomitant engagement of the CD40 ligand (CD40L) on the T cell with the DC CD40 receptor (Guermonprez et al., 2002). Another unique feature of DCs is their ability to present peptides generated from exogenous proteins on their MHC class I molecules, a phenomenon generally referred to as cross-presentation (Heath and Carbone, 2001). Indeed, it is due to these unique properties, that autologous DCs are considered ideal for the induction of antitumor responses (for reviews, see Gilboa et al., 1998; Nouri-Shirazi et al., 2000; Chen et al., 2000; Porgador et al., 1996) and are thus widely explored as potential cancer vaccines.

Attempts to develop novel approaches for the generation of cancer vaccines have taken two major routes. Some approaches make use of the complete antigenic repertoire of the tumor cells. This is accomplished by induction of T cells by irradiated tumor cells, genetically modified to express cytokines, co-stimulatory molecules or foreign MHC, by pulsing of DCs with tumor-derived heat shock proteins, whole tumor cell extracts or total RNA (a minute amount of which can easily be amplified) and fusion of DCs with tumor cells (Zhang et al., 1997; Gong et al., 1997; Gong et al., 2000). These strategies are applicable to many types of tumors and, in theory, can induce a wide spectrum of antitumor CTLs. However,

presentation of TAA-derived peptides of potential clinical benefit is not enriched and these protocols may thus fail to induce therapeutic CTLs (Sogn, 2000; Dalgleish, 2001). Furthermore, these procedures do not allow attribution of clinical response to particular antigens and, therefore, useful information cannot be deduced for broader implementation.

Other approaches for the generation of cancer vaccines are based on known TAAs. These include the design of peptide, DNA and recombinant viral vaccines, charging DCs with either purified tumor-associated proteins or TAA-derived peptides and presentation of TAA-derived peptides, which are produced following 10 gene delivery into autologous or syngeneic (in mice) DCs (for review, see Gilboa et al., 1998).

Indeed, some encouraging data showing CTL induction and vaccine efficacy came from animal studies exploring either type of above-described approaches. However, clinical success in human trials has so far been limited, with little 15 correlation between the observed number of specific anti-tumor CTLs and the actual clinical response (Sogn, 1998; Moingeon, 2001; Jager et al., 2002). This is attributed, in part, to requirement for help from CD4⁺ cells and to immunosuppressing cytokines produced by the tumor cells, but also to the fact that many of the identified MHC class I-associated TAA peptides are poorly presented 20 on the cell surface because of low level of protein expression and low affinity for their restricting MHC class I molecule (Watson et al., 1995; Vora et al., 1997).

Intracellular proteins, as well as soluble protein antigens delivered into the cytoplasm of a cell, are degraded into short peptides by a cytosolic proteolytic system present in all cells. Those proteins targeted for proteolysis often have a small 25 protein, called ubiquitin, attached covalently to a lysine-amino group near the amino terminal of the protein. These ubiquitin-protein complexes are degraded into a variety of peptides by a multifunctional protease complex called proteasome. Experimental evidence indicates that the immune system utilizes this general pathway of protein degradation to produce small peptides for presentation with class 30 I MHC molecules. The peptides, generated in the cytosol by the proteasome, are

translocated by a transporter protein, called TAP (for "transporter associated with antigen processing"), into the endoplasmic reticulum (ER), by a process that requires the hydrolysis of ATP. Within the ER membrane, newly synthesized class I α chain associates with calnexin until β_2m binds to the α chain. The class I α chain- β_2m heterodimer then binds to calreticulin and the TAP-associated protein tapasin. When a peptide delivered by TAP is bound to the class I molecule, folding of MHC class I is complete and it is released from the ER and transported to the surface of the cell. TAP has the highest affinity for peptides containing 8-13 amino acids. Peptides longer than the size required for MHC class I binding are further trimmed in the ER by assigned amino peptidases to acquire the optimal length.

A single cell can display thousands of different MHC class I bound peptides, most of them only at low frequency of less than 0.1% of the total. The density of MHC/peptide complexes on the cell surface determines the degree of T cell responsiveness (Levitsky et al., 1996; Tsomides et al., 1994; Gervois et al., 1996). CTL priming by a professional APC generally requires a higher density of specific complexes than that required on the surface of the target cell for activation of an armed effector CTL (Armstrong et al., 1998; Reis e Souza, 2001). The ability to generate high numbers of particular MHC class I/peptide complexes on the APC itself could, therefore, be of great value for elicitation of strong CTL responses, which may be effective against TAA-derived peptides of an otherwise limited distribution.

This realization has prompted attempts to enhance level of peptide presentation by APCs, either by increasing the intrinsic affinity of the peptide for the restricting MHC class I molecule, or by manipulations aiming at elevating the actual number of specific class I/peptide complexes on the cell surface. A recent study (Tirosh et al., 1999) has examined the effect of peptide affinity on CTL response it elicits, either by a chemical modification, which renders peptide binding to the class I groove irreversible, or by optimizing the MHC anchor residues of the peptide. Working with the TAP-deficient RMA-S cells, it was shown that improving the affinity of a murine TAA-derived peptide could indeed result in

significant enhancement of CTL induction and inhibition of tumor growth. However, at least in this particular system, there seems to exist an affinity ceiling, beyond which a corresponding augmentation in the magnitude of the immune response could not be achieved. An important observation in this study is of a 5 significant decrease in the initial number of specific complexes, both of low and high affinity peptides, which occurred in the first two hours post-loading. This finding underlines an inherent limitation associated with the transient nature of MHC-binding by exogenous antigenic peptides, and reinforces the prospects of genetic modification of DCs.

10 A number of studies have indeed attempted to increase the actual frequency of the desired antigenic class I complexes on the cell surface, through genetic engineering of improved class I-peptide ligands. For example, one group (Mottez et al., 1995; Lone et al., 1998) has constructed a chimeric MHC class I molecule, in which the antigenic peptide was covalently linked to the amino terminal of the α chain. These proteins were expressed on the surface of transfected cells and were 15 capable of eliciting a specific CTL response. However, using this approach, each antigenic peptide should be constructed with its own restricting α chain. To overcome this problem, another group (Uger and Barber, 1998) has attached the antigenic peptide to the amino terminal of the monomorphic β_2m . Primary T cells 20 from mice, which had been immunized with the specific peptide, could indeed selectively lyse transfected cells, expressing these constructs. However, the cells used for expression in this study were deficient in MHC class I expression, due to a TAP transporter mutation. Yet, in spite of lack of competition from cytosol-derived peptides, level of peptide presentation was limited. Using a similar design, another 25 study (Tafuro et al., 2001) has recently demonstrated reconstitution of MHC class I presentation in human cancer cells, but these, again, were class I-negative, due either to a TAP defect or to lack of β_2m expression. Although a non-mutated lymphoblastoid cell line was also included in this study and potentiated specific CTL lysis, there is no evidence as to the actual level of peptide presentation in these 30 cells.

Citation or identification of any reference in any section of this application shall not be construed as an admission that such reference is available as prior art to the present invention.

5 SUMMARY OF THE INVENTION

The present invention relates, in one aspect, to a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a β_2 -microglobulin molecule that is linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β_2 -microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope, wherein said antigenic peptide is not related to an autoimmune disease. This chimeric polypeptide is referred to herein as "double-chimeric β_2 -microglobulin" (dc β_2 m).

15 In one embodiment, an epitope, which is an antigenic determinant of one sole antigen, is linked to the amino terminal of the β_2 -microglobulin. In another embodiment, there are two or more epitopes that may be antigenic determinants of the same or of two or more different antigens. The epitopes/antigenic peptides may be derived from a tumor-associated antigen (TAA), from an infectious agent, e.g. a 20 bacterial or viral protein, or they are TCR idotypic peptides expressed by autoreactive T cells and BCR or antibody idotypic peptides expressed by autoreactive B cells.

In another aspect, the present invention relates to a vector comprising a DNA molecule of the invention.

25 In a further aspect, the present invention relates to antigen-presenting cells (APCs), which express a dc β_2 m encoded by the DNA molecule of the invention as defined above. Any suitable professional APC can be used according to the invention such as dendritic cells, macrophages and B cells. In a preferred embodiment, the APC is a dendritic cell. Transfection or transduction of the cells is

carried out by standard methods of recombinant DNA technology as well known to a person skilled in the art.

In one preferred embodiment, the APCs are capable of expressing a dc β_2 m polypeptide comprising at least one TAA peptide such as to present the TAA peptide(s) at a sufficiently high density to allow potent activation of peptide-specific cytotoxic T lymphocytes (CTL) capable of recognizing and binding to harmful tumor cells and causing their elimination or inactivation.

The present invention further provides a cancer vaccine comprising an agent selected from: (i) a DNA molecule encoding a dc β_2 m as defined herein wherein the at least one epitope linked to the amino terminal of β_2 m is derived from at least one TAA; (ii) an expression vector comprising such DNA molecule (i); (iii) antigen presenting cells expressing a dc β_2 m as defined herein wherein the at least one epitope linked to the amino terminal of β_2 m is derived from at least one TAA; (iv) antigen presenting cells (APCs) expressing a single-chimeric β_2 -microglobulin (sc β_2 m) molecule as defined herein consisting of a β_2 -microglobulin molecule linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β_2 -microglobulin molecule to the cell membrane; and (v) APCs as defined in (iv) that have been pulsed with at least one TAA peptide.

The present invention still further provides pharmaceutical compositions for use in inducing a class I-restricted CTL response in a mammal comprising cells expressing a dc β_2 m of the invention.

BRIEF DESCRIPTION OF THE FIGURES

Figs. 1A-1B depict the construction and expression of dc β_2 m. Fig. 1A is a sketch of the dc β_2 m polypeptide associated on the cell surface with a MHC class I heavy (α) chain, while the antigenic peptide is in the binding groove. The transmembrane and cytoplasmic domains are derived from either the mouse CD3 ζ chain or the MHC class I heavy chain H-2K^b, and are covalently attached, via a short bridge, to the carboxyl terminus of human or mouse β_2 m. The antigenic peptide

is attached to the amino terminal of β_2m via a short linker with the sequence G₄S(G₃S)₂. Fig. 1B is a scheme of the genetic construct: pr, promoter; lead, leader peptide; p, antigenic peptide; li, linker peptide; br, bridge. Important restriction sites are indicated.

5 Figs. 2A-2C show flow cytometry analysis of MD45 parental cells (Fig. 2A) and transfectants 425-44 (NP) cells (expressing NP₅₀₋₅₇ dc β_2m) (Fig. 2B) and 427-44 (Ha) cells (expressing the Ha₂₅₅₋₂₆₂ dc β_2m) (Fig. 2C). Cells were analyzed with primary antibodies against H-2K^k (clone AF3-12.1), h β_2m (clone BM-63) and K^k/Ha₂₅₅₋₂₆₂ complex (Fab13.4.1) and detected with secondary goat anti-mouse IgG (Fab-specific)-FITC conjugated polyclonal antibodies.

10 Fig. 3 shows stimulation of the MD45 transfectants 425-44, 427-24 and 892S-36 (see Table 1 hereinafter) by different MHC-I allele-specific antibodies. Indicated cells at 5 \times 10⁵/ml in 100 μ l were incubated in wells of a microtiter plate 15 pre-coated with the different antibodies at 5 μ g/ml and then subjected to an in-cell X-Gal staining. Anti-K^k is AF3-12.1 and anti-K^d is SF1-1.1. Anti-TCR is the hamster anti-mouse CD3 ϵ mAb 2C11, which served as a positive control for activation.

15 Figs. 4A-4C show FACS analysis of RMA (Fig. 4A), RMA-S (Fig. 4B) and transfectant Y317-2 (expressing OVA₂₅₇₋₂₆₄ linked to human membranal β_2m) cells 20 (Fig. 4C). Antibodies were: anti-H-2Db (28-14-8); anti-H-2Kb (20-8-4); anti-h β_2m (BM-63) and anti-K^b-OVA₂₅₇₋₂₆₄ (25-D1.16). Cells were grown for 24 hours in serum-free medium prior to staining at both 27°C and 37°C.

25 Figs. 5A-5G show that a K^b/OVA₂₅₇₋₂₆₄-specific T cell hybridoma is activated by cells expressing OVA₂₅₇₋₂₆₄ dc β_2m . B3Z cells, an H-2K^b-restricted OVA₂₅₇₋₂₆₄-specific T cell hybridoma, were incubated with: 5A. no stimulation; 5B. Plastic-bound (5 μ g/ml) anti-CD3 ζ mAb (2C11); 5C. RMA cells; 5D. RMA cells loaded with synthetic OVA₂₅₇₋₂₆₄ at 2 μ g/ml as a positive control; 5E. Y314-7 cells; 5F. Y317-2 cells; 5G. Y318-7 cells as a negative control. All cells were at 5 \times 10⁵/ml. Cells were stained with X-Gal and visualized under a microscope.

Figs. 6A-6B depict construction and expression of sc β_2 m. **Fig. 6A** is a sketch of the sc β_2 m polypeptide. The transmembrane and cytoplasmic domains are derived from either the mouse CD3 ζ chain or the MHC class I heavy chain H-2K^b, and are covalently attached, via a short bridge, to the carboxyl terminus of human or mouse β_2 m. **Fig. 6B** is a scheme of the genetic construct: pr, promoter; lead, leader peptide; p, antigenic peptide; li, linker peptide; br, bridge. Important restriction sites are indicated.

Fig. 7 shows stabilization of MHC class I molecules by membranal β_2 m. KD21-4 and KD21-6 RMA-S transfectants and parental RMA-S and RMA cells were grown in serum-free medium for 24 hours at 27°C and 37°C and then stained with anti-H-2Db (28-14-8) and anti-h β_2 m (BM-63) mAbs. FACS analysis was performed with FACSCalibur (BD Biosciences).

Fig. 8 is a graph showing the ability of KD21-6 and D323-4 transfectants to bind exogenously added synthetic OVA₂₅₇₋₂₆₄ peptide through H-2K^b, in comparison with parental RMA-S cells. The cells were grown at 37°C for 24 hours in serum-free medium and were then incubated for 42 hours with serial dilutions of synthetic OVA₂₅₇₋₂₆₄. Cells were stained with mAb 25.D1-16 and FACS analysis was performed with FACSCalibur. Mean fluorescence intensity was calculated using CellQuest software.

Fig. 9 is a graph showing generation of antigen specific CTLs following cell immunization. RMA-S and RMA-S/OVA (negative controls), RMA-S loaded with OVA₂₅₇₋₂₆₄ and RMA/OVA (positive controls), and transfectants Y317-2 and Y314-7 were injected i.p. twice at 10-day interval. Ten days after the second immunization, CTLs were prepared and the indicated cells (Y317-2, Y314-7 and RMA-S) were used as target cells in a cell cytotoxicity assay at effector/target ratio of 50:1. Histogram shows percent specific lysis.

Fig. 10 shows FACS analysis of RMA-S, KD21-6 and Y340-13 cells. Cells were analyzed with a primary antibody against h β_2 m (clone BM-63) and detected

with secondary goat anti-mouse IgG (Fab-specific)-FITC conjugated polyclonal antibodies.

DETAILED DESCRIPTION OF THE INVENTION

5 Duration of the functional MHC classI/peptide complex on the cell surface is governed by the affinity of the peptide for the MHC molecule. Dissociation of the peptide from its binding groove in the α heavy chain, results in practically irreversible disruption of the ternary complex formed between the α chain, β_2m and peptide. Both latter components are not anchored to the cell membrane and 10 immediately detach from the cell, while the α chain is later internalized. Stabilization of a particular class I/peptide complex by enabling fast re-association is therefore likely to result in high level of presentation of the antigenic peptide.

15 In one aspect, the concept underlying the present invention is that connecting at least one epitope to one end (the amino terminal) of β_2m and anchoring this polypeptide to the cell membrane through its other end (the carboxyl terminal), will provide an exceedingly high level of the antigenic peptide directly to the ER in a TAP- and proteasome-independent manner and substantially increase complex stability, and consequently, the level of presentation of this peptide.

20 WO 01/91698 of the same applicants, hereby incorporated by reference in its entirety as if fully disclosed herein, discloses the development by genetic engineering of a novel MHC class I configuration, in which the β_2m light chain is anchored to the cell membrane, while harboring an antigenic peptide related to an autoimmune disease fused to its amino terminal. Expression of this construct results in an exceptionally high level of the MHC-peptide complex on the surface of 25 transfected cells, despite competition from normally presented peptides. Thus, an influenza virus hemagglutinin-derived peptide (Ha₂₅₅₋₂₆₂), restricted by the mouse class I allele K^k, was linked to the amino terminal of β_2m by genetic engineering, while the carboxyl terminal was anchored to the membrane of transfected, K^k-expressing cells. Analyses performed with an anti-K^k mAb and another mAb, which 30 shows exquisite specificity to the K^k/Ha₂₅₅₋₂₆₂ complex, revealed high levels of the

complex on the surface of transfected cells. It should be emphasized that efficient pairing of $\text{Ha}_{255-262}$ with K^k through this double-chimeric $\beta_2\text{m}$ ($\text{dc}\beta_2\text{m}$) was achieved in-spite of strong competition from cytosolic-derived K^k -restricted peptides. Although data cannot be directly compared, it is to be noted that high level of surface class I-bound peptide by expression of non-membrane-attached $\beta_2\text{m}/$ peptide alone, could not be directly demonstrated in previous studies (Uger and Barber, 1998; Tafuro et al., 2001). Membranal anchorage of $\text{dc}\beta_2\text{m}$ is therefore likely to result in substantial augmentation in the overall density of desired class I antigenic peptides on the cell surface, thus offering a novel and unique tool for CTL induction.

The main objectives of the present invention are to develop both a cell based-vaccine and a DNA vaccine, based on membranal $\beta_2\text{m}$ carrying at least one antigenic peptide covalently bound to its amino terminal, wherein said antigenic peptide is not a peptide related to an autoimmune disease.

As used herein, the terms "antigenic peptide" or "peptide or epitope derived from an antigen" mean both a peptide having a sequence comprised within the sequence of said antigen or an altered sequence, in which one or more amino acid residues have been replaced by different amino acid residues, which may bear higher affinity for the MHC class I molecule.

Thus, in one aspect, the present invention provides a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a β_2 -microglobulin molecule that is linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β_2 -microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope, wherein said antigenic peptide is not related to an autoimmune disease.

In one embodiment, the polypeptide stretch at the β_2 -microglobulin carboxyl terminal consists of a bridge peptide, which spans the whole distance to the cell membrane, said bridge peptide being linked to a sequence which can exert the

required anchoring function. The bridge peptide has preferably about 10-15 amino acid residues, and more preferably, has a sequence comprised within the membrane-proximal sequence of a class I heavy chain HLA molecule. In a most preferred embodiment, this bridge peptide has 13 amino acid residues comprised within the 5 extracellular membrane-proximal sequence of the class I heavy chain HLA-A2 molecule, and is the peptide of SEQ ID NO:1, of the sequence LRWEPSSQPTIPI.

In one embodiment, the anchoring sequence to which the bridge peptide is linked is the full or partial transmembrane and/or cytoplasmic domain of a molecule selected from the group consisting of: (i) a human MHC class I molecule consisting of an HLA-A, HLA-B or HLA-C molecule; (ii) a costimulatory B7.1, B7.2 or CD40 molecule; and (iii) a signal transduction element capable of activating T cells or antigen-presenting cells.

In one embodiment, the anchoring residue (i) above is a sequence consisting of the transmembrane and cytoplasmic domains from the MHC class I heavy chain 10 HLA-A2 molecule, of the SEQ ID NO: 2, of the sequence:

VGIIAGLVLFGAVITGAVVAAVMWRRKSSDRKGGSYSQAASSDSAQ
GSDVSLTACKV

In another embodiment, the anchoring residue (iii) above is the intracellular region of a suitable signal transduction element capable of activating T cells such 20 as, but not being limited to, a component of T-cell receptor CD3 such as the zeta (ζ) or eta (η) polypeptide, a B cell receptor polypeptide or an Fc receptor polypeptide. The cytoplasmic regions of the CD3 chains contain a motif designated the immunoreceptor tyrosine-based activation motif (ITAM), which has been shown to associate with cytoplasmic tyrosine kinases and to participate in signal transduction 25 following TCR-mediated triggering. This motif is found in a number of other receptors including the Ig- α /Ig- β heterodimer of the B-cell receptor complex and Fc receptors for IgE and IgG, and three copies of it are found in the long cytoplasmic domains of the the ζ and η chains.

In a preferred embodiment, the anchoring residue of the chimeric molecule 30 comprises the transmembranal and cytoplasmic regions of the human T-cell

receptor CD3 ζ polypeptide, a signal transduction element capable of activating T cells.

In another embodiment, the signal transduction element capable of activating T cells comprises the transmembranal and cytoplasmic regions of a B-cell receptor polypeptide such as the Ig- α or Ig- β chain, the cytoplasmic tails in both being long enough to interact with intracellular signaling molecules. In a further embodiment, the signal transduction element comprises the transmembranal and cytoplasmic regions of Fc receptor polypeptides such as Fc ϵ RI, Fc γ RI or Fc γ RIII chains. Fc ϵ RI, a high-affinity receptor expressed on the surface of mast cells and basophils, 10 contains four polypeptide chains: an α and a β chain and two identical disulfide-linked γ chains that extend a considerable distance into the cytoplasm and each has an ITAM motif. Fc γ RI, or CD64, is the high affinity receptor for IgG, expressed mainly on macrophages, neutrophils, eosinophils and dendritic cells. It comprises an α chain and two disulfide-linked γ chains. This structure is also typical to 15 Fc γ RIII, or CD16, which is the low affinity receptor for IgG, found on NK cells, eosinophils, macrophages, neutrophils and mast cells. CD3 ζ chain is found instead of the γ chain in a fraction of Fc γ RIII.

In still a further embodiment, the anchoring residue to which the bridge peptide is linked through its carboxyl terminal is a glycosylphosphatidylinositol 20 (GPI)-anchor sequence, preferably the GPI-anchor peptide of SEQ ID NO:3, of the sequence FTLTGLLGTLVTMGLLT (from the protein DAF - complement decay-accelerating factor precursor or CD55 antigen; SWISSProt ID P08174, positions 365-381).

In one embodiment, the polynucleotide of the invention comprises a 25 sequence encoding a polypeptide as defined in which the at least one non-autoimmune disease related antigenic peptide comprising a MHC class I epitope is linked to the β_2 -microglobulin amino terminal directly. In another embodiment, the at least one antigenic peptide is linked to the β_2 -microglobulin amino terminal through a peptide linker.

In one embodiment, the at least one antigenic peptide is at least one antigenic determinant of one sole antigen.

In another embodiment, the at least one antigenic peptide is at least one antigenic determinant of each one of at least two different antigens.

5 In one preferred embodiment of the invention, the at least one non-autoimmune disease related antigenic peptide comprising a MHC class I epitope linked to the β_2 -microglobulin amino terminal is derived from a tumor-associated antigen (TAA) such as, but not limited to, alpha-fetoprotein, BA-46/lactadherin, BAGE (B antigen), BCR-ABL fusion protein, beta-catenin, CASP-8 (caspase-8), 10 CDK4 (cyclin-dependent kinase 4), CEA (carcinoembryonic antigen), CRIPTO-1 (teratocarcinoma-derived growth factor), elongation factor 2, ETV6-AML1 fusion protein, G250/MN/CAIX, GAGE, gp100 gp100 (glycoprotein 100)/Pmel17, HER-2/neu (human epidermal receptor-2/neurological), intestinal carboxyl esterase, 15 KIAA0205, MAGE (melanoma antigen), MART-1/Melan-A (melanoma antigen recognized by T cells/melanoma antigen A), MUC-1 (mucin 1), N-ras, p53, PAP (prostate acid phosphatase), PSA (prostate specific antigen), PSMA (prostate specific membrane antigen), telomerase, TRP-1/gp75 (tyrosinase related protein 1, or gp75), TRP-2, tyrosinase, and uroplakin Ia, Ib, II and III.

20 Examples of TAA peptides include, without being limited to, the following antigenic peptides:

- (i) the HLA-A2 restricted human alpha-fetoprotein peptide GVALQTMKQ (SEQ ID NO:4) associated with liver tumors;
- (ii) the HLA-Cw16 restricted human BAGE-1 peptide AARAVFLAL (SEQ ID NO:5);
- 25 (iii) the HLA-A2 restricted human BCR-ABL fusion protein (b3a2) peptide SSKALQRPV (SEQ ID NO:6) associated with chronic myeloid leukemia;
- (iv) the HLA-A24 restricted human beta-catenin peptide SYLDSGIHF (SEQ ID NO:7) associated with melanoma;

(v) the HLA-A2 restricted human CDK4 peptide ACDPHSGHFV (SEQ ID NO:8) associated with melanoma;

(vi) the HLA-A2 restricted human CEA peptide YLSGANLNL (SEQ ID NO: 9) associated with gut carcinoma;

5 (vii) the HLA-A68 restricted human elongation factor 2 peptide ETVSEQSNV (SEQ ID NO:10) associated with lung squamous cell carcinoma;

10 (viii) the HLA-A2 restricted human ETV6-AML1 fusion protein peptide RIAECILGM (SEQ ID NO:11) associated with acute lymphoblastic leukemia;

(ix) the HLA-A2 restricted human G250 peptide HLSTAFARV (SEQ ID NO:12) associated with stomach, liver and pancreas tumors;

15 (x) the HLA-Cw6 restricted human GAGE-1,2,8 peptide YRPRPRRY (SEQ ID NO:13);

20 (xi) the gp100 human peptides associated with melanoma HLA-A2 restricted KTWGQYWQV (SEQ ID NO:14), (A)MLGTHTMEV (SEQ ID NO:15), ITDQVPFSV (SEQ ID NO:16), YLEPGPVTA (SEQ ID NO:17), LLDGTATLRL (SEQ ID NO:18), VLYRYGSFSV (SEQ ID NO:19), SLADTNSLAV (SEQ ID NO:20), RLMKQDFSV (SEQ ID NO:21), RLPRIFCSC (SEQ ID NO:22), and the HLA-A3 restricted LIYRRRLMK (SEQ ID NO:23), ALLAVGATK (SEQ ID NO:24), IALNFPGSQK (SEQ ID NO:25) and ALNFPGSQK (SEQ ID NO:26);

25 (xii) the HLA-A2 restricted human HER-2/neu ubiquitous peptide KIFGSLAFL (SEQ ID NO: 27);

(xiii) the HLA-B7 restricted human intestinal carboxyl esterase peptide SPRWWPTCL (SEQ ID NO:28) associated with liver, intestine and kidney tumors;

30 (xiv) the HLA-B44 restricted human KIAA0205 peptide AEPINIQTW (SEQ ID NO:29) associated with bladder tumor;

(xv) the MAGE-1 peptides HLA-A1 restricted human EADPTGHSY (SEQ ID NO:30) and HLA-A3 restricted human SLFRAVITK (SEQ ID NO:31);

5 (xvi) the MAGE-3 peptides HLA-A1 restricted human EVDPIGHLY (SEQ ID NO:32) and HLA-A2 restricted human FLWGPRALV (SEQ ID NO:33);

10 (xvii) the HLA-A2 restricted human MART-1/Melan-A peptide (E)AAGIGILTV (SEQ ID NO:34) associated with melanoma;

15 (xviii) the HLA-A2 restricted human MUC-1 peptide STAPPVHNV (SEQ ID NO:35) associated with glandular epithelia carcinoma;

(xix) the HLA-A1 restricted human N-ras peptide ILDTAGREYY (SEQ ID NO:36) associated with melanoma;

(xx) the HLA-A2 restricted human p53 ubiquitous peptide LLGRNSFEV (SEQ ID NO:37);

15 (xxi) the HLA-A2 restricted human PSA peptides FLTPKKLQCV (SEQ ID NO:38) and VISNDVCAQV (SEQ ID NO:39) associated with prostate carcinoma;

20 (xxii) the HLA-A2 restricted human telomerase peptide ILAKFLHWL (SEQ ID NO: 40) associated with testis, thymus, bone marrow, and lymph nodes carcinomas;

25 (xxiii) the HLA-A31 restricted human TRP-1 peptide MSLQRQFLR (SEQ ID NO:41) associated with melanoma;

(xxiv) the HLA-A2 restricted human TRP-2 peptides LLGPGRPYR (SEQ ID NO:42), SVYDFFVWL (SEQ ID NO:43), and TLDSQVMSL (SEQ ID NO:44) associated with melanoma;

(xxv) the HLA-A68 restricted human TRP2-INT2 peptide EVISCKLIKR (SEQ ID NO:45); and

(xxvi) the HLA-A1 restricted human tyrosinase peptide KCDICTDEY (SEQ ID NO:46) associated with melanoma.

5 This list is presented only as examples of TAA peptides that can be used according to the invention. However, it is intended to encompass within the scope any TAA peptide known or to be discovered in the future as periodically published in Cancer Immunity, a Journal of the Academy of Cancer Immunology, at the website <http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm>.

10 In one embodiment of the invention, the polynucleotide encodes a polypeptide comprising at least one antigenic determinant of one sole TAA. In another preferred embodiment, the polynucleotide encodes a polypeptide comprising at least one antigenic determinant of each one of at least two different TAAAs.

15 Thus, in some applications according to the invention, it may be desired to link more than one epitope to the amino terminal of the anchored β_2m . In this way, the product of a single DNA molecule can mediate the induction of CTL clones directed at different epitopes from the same TAA, or from two or more different TAAAs, restricted by one or more HLA class I allelic products.

20 In one embodiment, the two or more epitopes may be derived from the same antigen. For example, at least 9 different HLA-A2 binding peptides and 4 different HLA-A3 binding peptides derived from the melanoma-associated antigen gp100 have been identified. A melanoma patient, who carries both HLA-A2 and HLA-A3, can, in principle, mount CTL responses to these 13 different gp100-derived peptides.

25 Thus, in one preferred embodiment, the at least one antigenic peptide is at least one HLA-A2 binding peptide and at least one HLA-A3 binding peptide derived from the melanoma-associated antigen gp100, more preferably at least one gp100 HLA-A2 binding peptide selected from the group consisting of SEQ ID NO: 14, 15, 16, 17, 18, 19, 20, 21 and 22, and at least one gp100 HLA-A3 binding peptide selected from the group consisting of SEQ ID NO: 23, 24, 25 and 26.

30 In another embodiment, this strategy can be employed to elicit a CTL response to more than one antigenic molecule by using a single gene encoding epitopes of two different TAAs. For example, the same sequence can harbor

peptides from gp100 and Melan-A/MART-1, both associated with melanoma, and harbor several HLA-A2-binding peptides, preferably at least one gp100 HLA-A2 binding peptide selected from the group consisting of SEQ ID NO: 14, 15, 16, 17, 5 18, 19, 20, 21 and 22, and at least one Melan-A/MART-1 HLA-A2 binding peptide selected from the group consisting of SEQ ID NO: 34. Similarly, peptides from different antigens, which bind different class I alleles can be incorporated on the same construct, e.g., HLA-A3-restricted gp100 and HLA-A2-restricted Melan-A/MART-1 peptide(s). Similarly, other combinations of different TAAs related to melanoma can be formed using one or more of the melanoma-associated TAAs 10 described above, e.g. peptides derived from beta-catenin, CDK4, gp100, Melan-A/MART-1, N-ras, TRP-1, TRP-2, and tyrosinase.

In another preferred embodiment of the invention, the at least one non-autoimmune disease related antigenic peptide comprising a MHC class I epitope linked to the β_2 -microglobulin amino terminal is derived from an antigen from a 15 pathogen selected from the group consisting of a bacterial, a viral, a fungal and a parasite antigen.

Examples of antigens derived from pathogenic, e.g. infectious, agents are, without being limited to, antigens derived from an organism selected from the group comprising: human immunodeficiency virus HIV (Takahashi et al., 1993), 20 varicella zoster virus, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), human cytomegalovirus (CMV), dengue virus, hepatitis A, B, C or E, respiratory syncytial virus, human papilloma virus, influenza virus, Hib, meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Streptococcus, Mycoplasma, Mycobacteria, Haemophilus, Plasmodium or 25 Toxoplasma, stanworth decapeptide; and TCR idiotypic peptides shared by autoreactive T cells (Cohen and Weiner, 1998; Offner et al., 1999; Kumar and Sercarz, 1999).

In one preferred embodiment, the pathogen antigen is a viral antigen such as, but not limited to, hepatitis virus, cytomegalovirus, or HIV viral antigen consisting 30 of an HIV protein selected from the group consisting of the HIV-1 regulatory

proteins Tat and Rev and the HIV envelope protein, in which case the antigenic peptide derived therefrom has the sequence RGPGRAFVTI (SEQ ID NO: 47).

In one embodiment of the invention, the polynucleotide encodes a polypeptide comprising at least one antigenic determinant of one sole pathogen antigen. In another preferred embodiment, the polynucleotide encodes a polypeptide comprising at least one antigenic determinant of each one of at least two different pathogen antigens. In this way, the product of a single DNA molecule can mediate the induction of CTL clones directed at different epitopes from the same viral antigen or from two or more different viral antigens, restricted by one or more HLA class I allelic products. For example, against AIDS, a combination of epitopes derived from each of the Tat, Rev and the HIV envelope proteins, may be used.

In yet a further embodiment of the invention, the at least one non-autoimmune disease related antigenic peptide comprising a MHC class I epitope linked to the β_2 -microglobulin amino terminal is at least one idotypic peptide expressed by autoreactive T lymphocytes. The idotypic peptide is preferably derived from a CDR (complementarity-determining region), more preferably CDR3, of an immunoglobulin or of a TCR chain, and it may also contain CDR flanking segments.

This embodiment is suitable for some applications according to the invention that may require the covalent linking of longer polypeptide stretches, which may contain one or more epitopes of unknown class I binding properties. For example, idotypic peptides derived from CDRs (especially CDR3) of immunoglobulin or TCR polypeptide chains can be employed for the induction of CTL response against lymphomas and leukemias of both B cell and T cell origin (Wen and Lim, 1993; Berger et al., 1998) or against autoreactive T cell clones (Kumar et al., 1995). However, many of these sequences are clonotypic in nature and there are no preliminary data concerning class I binding capacity of peptides they comprise. In such cases, longer DNA inserts, encoding, for example, not only the relevant CDR3 sequence, but also parts of its flanking FR3 and FR4 segments can be cloned directly from tumor cells or autoreactive T cell clones associated with an

autoimmune disease. If the encoded stretch contains one or more peptides which can bind one or more of the patient's HLA class I products, the obtained dc β 2m will induce CTLs of the corresponding specificities.

This task can be accomplished by the genetic insertion of the fragment 5 encoding the longer peptide into the expression vector between the sequence encoding the leader peptide (the leader peptide or signal peptide is the peptide stretch at the amino terminal of any newly synthesized polypeptide chain, which is to be translocated to the ER) and the sequence coding for the linker peptide. The fragment encoding the longer peptide can be prepared with the use of synthetic 10 oligonucleotides or as a PCR product (as for the CDR3 idiotypic peptides, using sets of FR3- and FR4-specific primers), or by any other procedure commonly used for molecular cloning. This design is based on the observations that MHC class I molecules can accommodate longer peptides than the canonical size of 8-10 amino acids. This most likely occurs by protrusion rather than by bulging (Stryhn et al., 15 2000) and shows preference to carboxyl terminal rather than to amino terminal extensions (Horig et al., 1999). It is predicted that in each assembly event in the ER of a relevant MHC class I molecule, a different peptide from the same dc β 2m gene product can associate with the nascent MHC class I heavy chain. Following this 20 association, the amino terminal protrusion can be trimmed by an ER aminopeptidase, operative in the early secretory pathway, as suggested by Snyder et al., 1994, and recently identified as the ER aminopeptidase ERAAP (Serwold et al., 25 2002) or ERAP1 (York et al., 2002; Saric et al., 2002), which trims precursors to MHC class I-presented peptides. The mature class I molecule will then be ready for transportation to the cell membrane. The rest of the long peptide may still link through its carboxyl terminal to the membranal β 2m. Hence, enhanced complex 30 stability and, concomitantly, high level of presentation are expected. In this manner, a panel of ligands can be formed in the APCs for induction of CTLs with different specificities, as the result of delivery of a single gene. This prediction also pertains to idiotypic peptides: an epitope can be embedded anywhere along the cloned sequence, and, similarly, the amino terminal protrusion will be cleaved. It is highly

likely that there will be a functional limitation to the size of the linked stretch, and that secondary structures formed within this stretch will interfere with the ability of at least some of the embedded epitopes to be properly presented.

5 In a more preferred embodiment of the invention, the polynucleotide of the invention as described hereinbefore is an expression vector and comprises a vector and regulatory sequences along with the polynucleotide sequence.

In another aspect, the present invention provides an expression vector comprising a polynucleotide of the invention as described hereinbefore.

10 Any suitable mammalian expression vector can be used such as, but not limited to, the pCI mammalian expression vectors (Promega, Madison, WI, USA), pCDNA3 expression vectors (Invitrogen, San Diego, CA) and pBJ1-Neo. The expression vector may also be a plasmid DNA in which the polynucleotide sequence is controlled by a virus, e.g. cytomegalovirus, promoter, or, most preferably, the expression vector is a recombinant viral vector such as, but not 15 limited to, pox virus or adenovirus or adeno-associated viral vector.

In a further aspect, the present invention provides an antigen-presenting cell (APC) transfected with a polynucleotide comprising a sequence encoding a dc β_2 m of the invention, i.e. a polypeptide comprising a β_2 -microglobulin molecule that is linked through its carboxyl terminal to a polypeptide stretch that allows the 20 anchorage of the β_2 -microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope.

The APC may be a macrophage, a B cell, a fibroblast and, more preferably, a dendritic cell. In a preferred embodiment, the antigenic peptide is a peptide not related to an autoimmune disease.

25 In one embodiment, the at least one antigenic peptide in the antigen-presenting cell is at least one peptide derived from at least one TAA. Said cell is capable of presenting the at least one TAA peptide at a sufficiently high density to allow potent activation of peptide-specific cytotoxic T lymphocytes (CTL) capable of recognizing and binding to harmful tumor cells and causing their elimination or 30 inactivation.

In another embodiment, the at least one antigenic peptide in the antigen-presenting cell is at least one peptide derived from an antigen from a pathogen selected from the group consisting of a bacterial, a viral, a fungal and a parasite antigen.

5 In another embodiment, the at least one antigenic peptide in the antigen-presenting cell is at least one idiotypic peptide expressed by autoreactive T lymphocytes, preferably at least one idiotypic peptide derived from a CDR, more preferably CDR3, of an immunoglobulin or of a TCR chain, that may also contain CDR flanking segments.

10 Any of the techniques which are available in the art may be used to introduce the recombinant nucleic acid encoding the polypeptide into the antigen presenting cell. These techniques are collectively referred to as transfection herein and include, but are not limited to, transfection with naked or encapsulated nucleic acids, cellular fusion, protoplast fusion, viral infection, cellular endocytosis of calcium-nucleic acid microprecipitates, fusion with liposomes containing nucleic acids, and electroporation. Choice of suitable vectors for expression is well within the skill of the art. Antigen expression may be determined by any of a variety of methods known in the art, such as immunocytochemistry, ELISA, Western blotting, radioimmunoassay, or protein fingerprinting.

15

20 In an additional aspect of the present invention, a DNA vaccine is provided comprising a polynucleotide of the invention or an expression vector of the invention, both as described hereinabove.

25 In one embodiment, there is provided a DNA vaccine for prevention or treatment of cancer comprising a polynucleotide that encodes a polypeptide comprising at least one antigenic determinant of at least one TAA.

In another embodiment, there is provided a DNA vaccine for prevention or treatment of a disease caused by a pathogenic organism comprising a polynucleotide that encodes a polypeptide comprising at least one antigenic determinant of at least one pathogenic antigen.

The DNA vaccines may be constructed according to methods known in the art. Genes in plasmid expression vectors are expressed in vivo after intramuscular (i.m.) or subcutaneous (s.c.) injection and this expression stimulates an immune response against the plasmid-encoded proteins. The same or better effect is obtained 5 replacing the plasmid by a viral vector.

In one embodiment, the DNA vaccine is a naked DNA vaccine. It may contain a plasmid DNA that contains the polynucleotide of the invention controlled by a cytomegalovirus (CMV) promoter. When the plasmid is introduced into mammalian cells, cell machinery transcribes and translates the gene. The expressed 10 protein (immunogen) is then presented to the immune system where it can elicit an immune response. One method of introducing DNA into cells is by using a gene gun. This method of vaccination involves using pressurized helium gas to accelerate DNA-coated gold beads into the skin of the vaccinee.

DNA vaccines are capable of eliciting both strong humoral and cell-mediated 15 immunity. Therefore DNA immunization represents a new approach for prevention (vaccination) and treatment (immune-based therapy) of infectious and neoplastic diseases.

In yet a further aspect of the invention, there is provided a cellular vaccine which comprises an antigen presenting cell of the invention as described 20 hereinbefore. The antigen presenting cell is preferably a dendritic cell, but may also be a macrophage, a B cell and a fibroblast. The cells in the cellular vaccine may be autologous, allogeneic or xenogeneic cells.

The present invention provides cellular vaccines which comprise an antigen presenting cell that is capable of presenting at least one antigenic peptide 25 comprising an epitope of at least one antigen and has the ability to induce potent CTL responses against the desired antigen(s). Vaccination, as used herein, refers to the step of administering the cellular vaccine to a mammal to induce such an immune response, for example, to prevent or treat a tumor or a disease caused by an infectious agent in a mammal.

5 The presentation of the at least one antigenic peptide by the APCs in the cellular vaccine can be achieved by transfecting the APCs with the polynucleotide of the invention, or by transducing the APCs with a virus encoding the polynucleotide of the invention or by incubating said antigen presenting cells with a polynucleotide encoding said at least one antigenic peptide.

In one embodiment, the invention provides a cellular vaccine for prevention or treatment of cancer wherein the antigen presenting cell presents at least one peptide derived from at least one tumor associated antigen.

10 In an additional aspect, the present invention provides a cellular vaccine for the prevention and/or treatment of a cancer comprising antigen presenting cells which express a sc β ₂m, i.e. a β ₂-microglobulin linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β ₂-microglobulin molecule to a cell membrane, wherein said polypeptide stretch consists of a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being 15 linked to a sequence which can exert the required anchoring function, and wherein said cells have been pulsed with at least one antigenic peptide derived from at least one tumor associated antigen.

20 In still a further aspect, for the treatment of cancer it is envisaged by the present invention to encompass tumor cells transfected with a polynucleotide comprising a sequence encoding a sc β ₂m, i.e. a polypeptide comprising a β ₂-microglobulin molecule that is linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β ₂-microglobulin molecule to the cell membrane. The sc β ₂m will enhance expression of the MHC class 1 molecules on the cell surface of the tumor cells.

25 In this aspect, it is known that tumor cells, which manifest impaired expression of MHC class I MHC molecules and are thus poorly immunogenic, can induce antitumor CTL activity upon transfection of MHC class I genes (Feldman and Eisenbach, 1991). The level of MHC class I expressed on the surface of tumor cells is a key factor, which governs immunogenicity of the tumor, and is amenable 30 to genetic modification. It is evident from Table 2 hereinafter that the mere

expression of sc β 2m results in 3-4-fold enhancement in the level of H-2K^k. This effect can be harnessed to augment MHC class I expression by tumor cells. For example, tumor cells can be derived from the patient, transduced ex-vivo with a recombinant virus encoding membranal h β 2m and expanded. Following their 5 mitotic inactivation, transduced cells will be introduced back to the patient to serve as immunogens capable of eliciting a tumor-specific CTL response. This response may then target also unmodified tumor cells, provided they still express MHC class I molecules at a level sufficient for recognition by the armed effector CTLs.

In another embodiment, the invention provides a cellular vaccine for 10 prevention or treatment of a disease caused by a pathogenic organism wherein the antigen presenting cell presents at least one peptide derived from a pathogenic antigen.

In a further additional aspect, the present invention provides a cellular vaccine for the prevention and/or treatment of a disease caused by a pathogen 15 comprising antigen presenting cells which express a sc β 2m, i.e. a β ₂-microglobulin linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β ₂-microglobulin molecule to a cell membrane, wherein said polypeptide stretch consists of a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a sequence which can exert 20 the required anchoring function, and wherein said cells have been pulsed with at least one antigenic peptide derived from at least one antigen of said pathogen.

The cellular vaccine may be administered subcutaneously, intradermally, intratracheally, intranasally, or intravenously. The cells may be suspended in any pharmaceutically acceptable carrier, such as saline or phosphate-buffered saline.

25 In still another aspect, the present invention provides a method of immunizing a mammal against a tumor-associated antigen comprising the step of: immunizing the mammal with an antigen presenting cell which has been transfected with, or transduced with, or loaded with, a recombinant nucleic acid molecule comprising a sequence encoding a polypeptide comprising a β ₂-microglobulin 30 molecule that is linked through its carboxyl terminal to a polypeptide stretch that

allows the anchorage of the β_2 -microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope of at least one tumor-associated antigen, or with a cellular vaccine comprising said antigen presenting cell, wherein the mammal mounts a cytotoxic immune response against the at least one tumor-associated antigen, and wherein the 5 antigen presenting cell presents said at least one antigenic peptide.

In yet another aspect, the present invention provides a method of immunizing a mammal against a disease caused by a pathogenic organism comprising the step of: immunizing the mammal with an antigen presenting cell which has been 10 transfected with, or loaded with, a recombinant nucleic acid molecule comprising a sequence encoding a polypeptide comprising a β_2 -microglobulin molecule that is linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β_2 -microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope 15 of a pathogenic antigen, or with a cellular vaccine comprising said antigen presenting cell, wherein the mammal mounts a cytotoxic immune response against the pathogenic antigen, and wherein the antigen presenting cell presents said at least one antigenic peptide.

In still a further aspect, the present invention provides a method for the 20 prevention and/or treatment of a cancer or of a disease caused by a pathogen which comprises administering to a patient in need thereof antigen presenting cells which express a chimeric polypeptide comprising β_2 -microglobulin linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β_2 -microglobulin molecule to a cell membrane, wherein said polypeptide stretch 25 consists of a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a sequence which can exert the required anchoring function, and wherein at least one antigenic peptide derived from at least one tumor associated antigen or from an antigen of said pathogen is exogenously loaded on said antigen presenting cells, preferably in the grooves of the MHC

complex formed by the association of the chimeric polypeptide with the endogenous MHC molecule component.

In yet still a further aspect, the present invention provides pharmaceutical compositions. In one embodiment, the composition comprises as an active ingredient at least one polynucleotide or an expression vector of the invention, and a pharmaceutically acceptable carrier. The polynucleotide may comprise a sequence encoding a polypeptide comprising at least one antigenic peptide derived from at least one tumor associated antigen, or at least one antigenic peptide derived from a pathogenic antigen. In another embodiment, the pharmaceutical composition comprises as an active ingredient at least one antigen presenting cell of the invention, and a pharmaceutically acceptable carrier.

Good cancer vaccines should induce a protective CTL response directed at MHC class I peptides derived from TAAs. The pivotal APC in CTL priming is the dendritic cell (DC), which has indeed been widely utilized in the design of cancer vaccines. In particular, DCs are attributed a critical role in DNA immunization, and direct presentation of peptides derived from expression of genetic material internalized by DCs is considered a major route for CTL induction. While magnitude of a CTL response correlates with density of specific MHC-peptide complexes on the APC surface, many TAA peptides have low affinity for the class I molecule and are presented at sub-optimal densities. Combined with the limiting expression level normally achieved following administration of non-replicating DNA, DNA immunization against TAAs usually falls short from achieving the anticipated effect.

The double-chimeric β_2m (dc β_2m) polypeptide design of the present invention creates an entirely novel MHC class I entity, which may offer a great advantage over current strategies as a means to augment CTL induction. The membrane anchorage of the β_2m molecule can be achieved by covalently linking to its carboxyl terminal a peptide bridge, which spans the whole distance to the cell membrane, and is supplemented by an anchoring sequence such as the transmembrane and cytoplasmic domains derived from another cell surface protein.

Following dissociation of β_2m -linked peptide from the α chain, this design is expected to prevent detachment of the β_2m /peptide from the cell membrane. Membrane anchorage should immensely increase the local concentration of $dc\beta_2m$ in the cell membrane, and allow rapid re-formation or de-novo formation of the 5 specific MHC class I complex upon peptide dissociation. This will significantly prolong the actual half-life of the complex, and increase its membranal level.

Chimeric β_2m polypeptides having a sole antigenic peptide linked to their amino terminal, which are provided exogenously, have been shown to associate with α chains on the cell surface and to form full MHC class I complexes (Uger and 10 Barber, 1998; Tafuro et al., 2001; Uger et al., 1999; White et al., 1999). According to the present invention, it is also assumed that re-association will take place on the cell membrane but obeying kinetics of lateral diffusion. Furthermore, but not less important, the high local peptide concentration, the membranal form of β_2m and the anticipated proteasome- and TAP-independence according to the invention, are all 15 expected to render initial assembly of the specific, intact MHC class I complex in the ER highly favorable, compared with assembly involving processing and transportation of conventional, cytosolic peptides.

As used herein, the term "double-chimeric β_2 -microglobulin" ($dc\beta_2m$) refers to a molecule of β_2m having at least one epitope/antigenic peptide bound to the 20 amino terminal and an anchor domain bound to the carboxyl terminal, wherein said anchor domain is composed of a polypeptide stretch consisting of a bridge peptide, which spans the whole distance to the cell membrane, and a peptide sequence that allows the anchorage of the β_2 -microglobulin molecule to the cell membrane. The term "single-chimeric β_2 -microglobulin" ($sc\beta_2m$), when used herein, refers to a 25 molecule of β_2m having only the anchor domain, as defined above, but no antigenic peptide at the amino terminal.

The realization that vaccination with naked DNA results in long-lasting protein expression and stimulation of specific humoral and cellular immune responses, has made a large impact in the field of vaccine design (see Gurunathan et

al., 2000 for review). Numerous studies, which have shown that DNA vaccines induce potent MHC class I-restricted CTL responses against TAAs, have suggested that this modality may be particularly useful for the treatment of cancer, and have prompted the development of a variety of DNA vaccine strategies (see review by 5 Benton and Kennedy, 1998). First human trials of cancer DNA vaccines have been initiated, but it is too early to evaluate their efficacy. There is compelling evidence that a CTL response following DNA administration can be induced by directly transfected DCs (Porgador et al., 1998), although other mechanisms, such as direct transfection of somatic cells or cross presentation by DCs, are also considered.

10 According to the present invention, direct delivery of the $dc\beta_2m$ polypeptide produced by DCs, which express the introduced gene, to surface MHC class I molecules for peptide presentation is expected to result in considerable enhancement in peptide level, and hence, in vaccine efficacy, compared with that achieved by conventional antigen processing and presentation.

15 The present invention thus provides a novel and broadly-applicable strategy for efficient induction of antigen-specific CTLs, which is based on the ability of $dc\beta_2m$ to markedly enhance presentation of antigenic peptides. The CTL response may be optimized by a regimen of two or more booster administrations. Cocktails of two or more CTL inducing peptides are employed to optimize epitope and/or 20 MHC class I restricted coverage.

25 For the purposes of the present invention, the biochemical and immunological properties associated with this mode of presentation are first explored *in vitro* in transfected cell lines, and its *in vivo* function is then assessed in a mouse melanoma tumor model, applying transfected APC cell lines, naked DNA immunization and adoptive transfer of syngeneic APCs from transgenic mice.

Defining various parameters, which govern expression of $dc\beta_2m$, and establishing its actual potential as a tumor vaccine in a mouse model are expected to pave the way for the design of a novel modality of human cancer vaccines. The most suitable effector cells for this purpose are autologous DCs, which can be

relatively easily transduced to express foreign genes (Hadzantonis and O'Neill, 1999; Bubenik, 2001).

The inability to present low affinity peptides at densities required for potent activation of the entire repertoire of peptide-specific CTL clones is considered a major obstacle in many of the current protocols, which aim at producing DC-based cancer vaccines. According to the present invention, it is expected that the dc β ₂m-based constructs will increase the apparent affinity of the peptide to the MHC molecule and, thus, the dc β ₂m-mediated presentation on DCs should allow TAA-derived peptides with limiting affinity for the restricting MHC class I product to be presented by the DCs at sufficiently high density. This is one of the expected advantages of the present invention in comparison to previously proposed approaches for the development of cancer vaccines based on dendritic cells.

Some TAAs are expected to play an active part in the induction of central tolerance in the thymus, thus allowing only CTLs of low avidity to mature (Gilboa, 1999). These may include TAAs which are classified as differentiation antigens (for example MART-1/Melan A, gp100 and tyrosinase), and, probably to a lesser extent, normal gene products with highly restricted tissue distribution (such as MAGE, BAGE and GAGE). The strategy of the present invention can be efficient in activating such low avidity CTLs.

Tumors often evade the immune system by reduction in MHC class I peptide presentation to CTLs by downregulation of either components of the proteasome complex or TAP (for review see Benton and Kennedy, 1998). Enhancement of TAA peptide presentation by such tumors following gene delivery activates CTLs, which can respond also to non-modified tumor cells (Sherritt et al., 2001), provided the density of class I tumor-associated epitopes exceeds a functional threshold of these CTLs. Hence, dc β ₂m or sc β ₂m are expected to induce CTLs not only in professional APCs as dendritic cells but, in certain cases, also when expressed in tumor cells.

The approach of the proposed invention offers broad applicability and requires only straightforward genetic engineering: since human β ₂m is

monomorphic, only one cloning expression cassette should be prepared, to which the segment encoding any antigenic peptide of interest can easily be inserted.

The invention will now be illustrated by the following non-limiting examples.

5

EXAMPLES

Materials and Methods

(i) *Cells.* MD45 is an H-2D^b-allospecific mouse H-2^{k/d} CTL hybridoma of 10 BALB/c origin (Faufmann et al., 1981). RMA-S is a mutant cell line derived from the C57BL/6 lymphoma RMA (H-2^b), which has defects in peptide presentation by class I MHC molecules due to loss of functional expression of the TAP component TAP-2. These cells can be loaded exogenously with high levels of MHC class I compatible peptides. RMA/OVA and RMA-S/OVA are clones of these two cells 15 transfected with the full-length chicken ovalbumin gene. B3Z is an H-2K^b-restricted, OVA₂₅₇₋₂₆₄-specific CTL hybridoma, harboring the NFAT-LacZ reporter gene (Sanderson and Shastri, 1994), and is a gift from Dr. N. Shastri, University of California, Berkeley. Three clones of the mouse melanoma B16, a spontaneously-arising melanoma of C57BL/6 origin are used: F10.9 is a spontaneously 20 metastasizing clone of the B16-F10 line, K1 is an H-2K^b transfectant of F10.9 (Porgador et al., 1989) and MO5 is a chicken ovalbumin-transfected variant of the B16 melanoma. C57BL/6-derived T cell Line A, reactive with TRP-2 peptide 181-188 (TRP-2₁₈₁₋₁₈₈) (Bloom et al., 1997), is available from Dr. J. Yang, NCI, NIH, USA.

25 (ii) *Antibodies.* Fab13.4.1 is a Fab fragment specific to Ha₂₅₅₋₂₆₂ in the context of K^k, and was a gift from Dr. J. Engberg, University of Copenhagen (Andersen et al., 1996). AF3-12.1 is an anti-K^k mAb (Pharmingen). BM-63 is an anti-human β_2 m mAb (Sigma). 20.8.4 is an anti-H-2K^b mAb. 28-14-8 is an anti-H-2Db mAb. 25-D1.16 is specific to the complex H-2K^b/OVA₂₅₇₋₂₆₄ (Porgador et al., 30 1997). These latter antibodies are available from Dr. L. Eisenbach, Weizmann

Institute of Science, Rehovot, Israel.

5 (iii) *DNA transfection.* 5-10x10⁶ RMA-S cells in 0.8 ml were mixed in 4 mm sterile electroporation cuvette (ECU-104, EquiBio, Ashford, UK) with 10-20 µg DNA of the constructed plasmid and placed on ice. Transfection was performed by electroporation using Easyject Plus electroporation unit (EquiBio, Ashford, UK) at 350V, 750 µF. Cells were resuspended in fresh medium and cultured for 24-48 hours in 96-well plates prior to addition of the selecting drug (1 mg/ml G418). Resistant clones were first expanded in 24-well plates and analyzed for expression of the introduced gene by FACS.

10 (iv) *FACS analysis.* Cells were stained with indicated antibodies according to standard procedures and were subjected to flow cytometry analysis. 10⁶ cells were washed with phosphate-buffered saline (PBS) containing 0.02% sodium azide and incubated for 30 minutes on ice with 100 µl of the anti-human β₂m mAb (Sigma) at 10 µg/ml or the same concentration of a control antibody (or no 15 antibody). Cells were then washed and incubated on ice with 100 µl of 1:100 dilution of goat anti-mouse IgG (FAB specific)-FITC conjugated polyclonal antibody (Sigma) for 30 minutes. Cells were washed and resuspended in PBS and analyzed by a FACSCalibur (BD Biosciences, Mountain View, CA). Statistical analysis was performed with the FACSCalibur CellQuest software. Quantitative 20 analysis of cell surface antigens was performed with QIFIKIT (DAKO, Carpinteria, CA) according to the manufacturer's instructions.

25 (v) *Cell stimulation assay.* Cells at 5x10⁵ cells/ml were incubated overnight in 96-well plates in the presence of 5 µg/ml antibody (immobilized overnight and washed 3 times in PBS) or with target cells at 5x10⁵ cells/ml. Total volume: 0.1 ml.

25 (vi) *In-cell X-Gal staining.* Cells in 96-well plates were washed twice with PBS and fixed with 0.25% glutaraldehyde for 15 min, washed 3 times in PBS, incubated for 4 hours with 100 µl of X-Gal solution {0.2% X-Gal, 2mM MgCl₂, 5mM K₄Fe(CN)₆·3H₂O, 5mM K₃Fe(CN)₆ in PBS} and scored under the microscope for blue staining.

30 (vii) *Immunization of mice.* Immunization was carried out with peptide

loaded RMA-S cells, RMA-S, RMA-S/OVA and RMA/OVA and OVA₂₅₇₋₂₆₄-dc β ₂m-expressing RMA-S transfectants (Y314-7 and Y317-2): RMA-S cells were incubated at 2x10⁶ cells/ml for 2 hours with 200 μ g/ml of OVA₂₅₇₋₂₆₄. Mice were immunized twice i.p. with 2x10⁶ irradiated (50 Gy) cells, at 10 day intervals.

5 (viii) *Cytotoxicity assay.* Ten days after last immunization spleens were removed and single cell suspension were prepared. Splenocytes were restimulated with irradiated, mitomycin-C-treated tumor cells or target cells. Restimulated lymphocytes were maintained for another 4 days. Viable lymphocytes were separated on Lympholyte-M gradient (Cedarlane, Ontario, Canada) and 10 resuspended at 5 x 10⁶/ml with lymphocyte medium. Lymphocytes were mixed at different ratios (1:100, 1:50, 1:25 and 1:12.5 target to effector) with ³⁵S-methionine-labeled target cells (tumor cells or peptide-presenting cells). CTL assays were carried out following standard procedures.

15 15 Example 1. Expression of dc β ₂m designed for T cell re-programming

The general schemes of genetic constructs encoding dc β ₂m and of the polypeptide product associated with an MHC class I heavy chain are illustrated in Fig. 1. Table 1 summarizes all different single and double chimeric β ₂m expression plasmids generated in this system as well in the tumor experimental system, which 20 will be described below.

Table 1. Double and single chimeric β ₂m constructs and transfected clones expressing them

Peptide	Allele	β ₂ m	Anchor	Cell (H-2)	Clone
IV Ha255-262	K ^k	human	none	MD45(k/d)	840-7
IV Ha255-262	K ^k	human	CD3 ζ	MD45	427-24
IV NP50-57	K ^k	human	CD3 ζ	MD45	425-44
Insulin B15-23	K ^d	mouse	CD3 ζ	MD45	829S-36

OVA257-264	K ^b	mouse	H-2K ^b	RMA-S(b)	Y314-7
OVA257-264	K ^b	human	H-2K ^b	RMA-S	Y317-2
TRP-2181-188	K ^b	mouse	H-2K ^b	RMA-S	Y313-10
TRP-2181-188	K ^b	human	H-2K ^b	RMA-S	Y318-7
none	-	human	CD3 ζ	RMA-S	KD21-4, 6
none	-	human	H-2K ^b	RMA-S	D323-4
none	-	human	CD40	B3Z(b)	Y340-13

In our previous patent application, WO 01/91698, herein incorporated by reference as if fully disclosed herein, it was aimed to redirect effector T cells against other, harmful T cells, through the CD3 ζ chain portion. In the experimental system described in WO 01/91698, two special mammalian expression cassettes were constructed, which allow the single-step insertion of a stretch coding for an antigenic peptide, so as to create dc β_2 m of either human or mouse origin. The bridging peptide, derived from the human MHC class I molecule HLA-A2, was the extracellular 13-amino acid stretch of SEQ ID NO:1, which is most proximal to the cell membrane, and the transmembrane and cytoplasmic domains were those of the mouse CD3 ζ chain. The sequence encoding the K^k-restricted influenza virus hemagglutinin peptide Ha₂₅₅₋₂₆₂ was cloned into the unique cloning sites in the human β_2 m cassette. Plasmid DNA was transfected into the MD45 hybridoma, and one stable transfectant, designated 427-24 (Ha), was further analyzed. Another MD45 transfectant, designated 425-44 (NP), was generated, which similarly expresses the K^k-restricted influenza virus nucleoprotein peptide NP₅₀₋₅₇. FACS analysis was performed with the anti-h β_2 m and anti-H-2K^k antibodies and with the K^k/Ha₂₅₅₋₂₆₂ complex-specific Fab13.4.1. Fig. 2 shows intensive staining of 427-24, but no detectable staining of the control cell 425-44 or of the parental MD45. Quantitative analysis of antigen level on the surface of both transfectants and parental MD45 cells is shown in Table 2 and reveals occupation of 20% of surface H- K^k molecules of 427-24 cells by the Ha₂₅₅₋₂₆₂ peptide.

Table 2. Quantitative analysis of surface antigens of transfectants 425-44 and 427-24 and parental MD45 cells*

5	<u>Cell</u>	<u>Antibody</u>		
		Anti-H-2K ^k	Anti-h β 2m	Fab13.4.1
	MD45	10,909	0	0
	<u>425-44</u>	37,604	466,704	0
	<u>427-24</u>	28,637	173,143	5,715

10 * Cells were stained with the anti-H-2K^k mAb AF3-12.1, the anti-h β 2m mAb BM-63 and Fab13.4.1, specific to the K^k/Ha₂₅₅₋₂₆₂ complex, and analyzed with QIFIKIT (Dako), using goat anti-mouse IgG (Fab-specific)-FITC conjugated polyclonal antibodies. Mean fluorescence intensities were derived with FACSCalibur software and standard curve was generated from the linear regression of five points at 3,600,
15 16,000, 53,000, 218,000 and 620,000 mouse IgG molecules per bead, using Excel.

20 It should be noted that the complex-specific antibody (Fab13.4.1) is a Fab, whereas the anti-H-2K^k is an intact IgG. Therefore, the actual occupation of H-2K^k molecules on the surface of 427-24 may in fact be higher. Also noteworthy is the 3-fold increase in the total amount of H-2K^k in both transfectants 425-44 and 427-24, compared with the parental MD45 cells.

25 It is conceivable that, on the cell surface, dc β 2m polypeptides can associate with MHC class I allelic products other than the restricting one. In this scenario, the flexible peptide linker allows the covalently linked antigenic peptide to be situated away from the MHC binding groove, which is occupied by a conventional peptide. In order to test this structural prediction we designed a functional assay, based on the ability of our transfectants to respond to stimulation by Lac-Z production. If this indeed occurs, cells expressing an H-2K^k binding peptide will also be activated by an anti-H-2K^d mAb, and vice-versa. As shown in Fig. 3, this is really the case. This 30 finding implies to an elevated pool of membranal β 2m, which can become available by lateral diffusion for binding to their cognate MHC class I alleles following dissociation of their original peptide.

Example 2. Construction and expression of dc β ₂m molecules harboring antigenic peptides of the B16 mouse melanoma model

The APCs for the animal studies are based on the commonly used RMA and RMA-S H-2^b cell lines. In the animal experiments, focus is on a mouse melanoma expressing a natural K^b-restricted, TAA-derived peptide, and, as a control for peptide specificity, a derivative of the same mouse melanoma is employed presenting another, highly immunogenic K^b-restricted peptide, following DNA transfection.

10 B16 is a spontaneous murine (m) melanoma originating in C57BL/6 mice. B16-F10.9 is a high metastatic line of B16, which shows a low cell surface expression of H-2K^b, and K1 is a low metastatic B16 variant, expressing high level of H-2K^b following DNA transfection (Porgador et al., 1989). TRP-2 was recently identified as a tumor rejection antigen for the B16 melanoma (Bloom et al., 1997).

15 15 TRP-2₁₈₁₋₁₈₈, (VYDFFVWL – the peptide of SEQ ID NO: 43, in which the residue S at the amino terminal is absent) is a K^b-restricted peptide from TRP-2, and is a major peptide epitope in the induction of tumor-reactive CTLs, which mediate tumor rejection. MO5 is a chicken ovalbumin-transfected variant of the B16 melanoma. It presents the peptide OVA₂₅₇₋₂₆₄ (SIINFEKL – SEQ ID NO: 48),

20 20 possessing H-2K^b anchor residues F at position 5 and L at position 8) in the context of K^b.

For further studies, including the B16 model, we replaced both the peptide bridge and the transmembrane and cytoplasmic domains of membranal β ₂m with those of the H-2K^b molecule. A new XhoI/NotI fragment (see Fig. 1), encoding this 25 polypeptide stretch, was produced, bearing the DNA sequence of SEQ ID NO: 49:

*gag ccc tcg agc tcc act gtc tcc aac atg gcg acc gtt gct gtt ctg gtt gtc ctt gga
gct gca ata gtc act gga gct gtg gtg gct ttt gtg atg aag atg aga agg aca aca ggt gga
aaa gga ggg gac tat gct ctg gct cca ggc tcc cag acc tct gat ctg tct ctc cca gat tgt aaa
gtg atg gtt cat gac cct cat tct cta gcg tga.*

From the 11th codon (gcg) till the end this sequence encompasses the intact transmembrane and cytoplasmic portion of H-2K^b (positions 658-852 in GenBank accession J00400). The bridge is LRWEPSSTVSNM (SEQ ID NO: 50), a fusion between the connecting peptide of HLA-A2 (at the carboxyl terminal) and H2-K^b. It is encoded by the sequence ctg aga tgg gag ccC TCG AGC tcc act gtc tcc aac atg, (SEQ ID NO: 51) with an XhoI site incorporated into the sequence.

5 The sequence of the sense primer comprises 2b protection and an XhoI site followed by the 3' part of the H-2K^b connecting peptide"

5' CCC TCG AGC TCC ACT GTC TCC AAC ATG GCG 3' (SEQ ID NO: 52)

10 The sequence of the reverse primer comprises 3b protection, a NotI site and it corresponds to GenBank accession J00400 positions 858-875:

5' CGC GCGG CCGC AAG TCC ACT CCA GGC AGC 3' (SEQ ID NO: 53)

The fragment was produced by RT-PCR performed on mRNA prepared from RMA (H-2^b) cells.

15 The sequences encoding both Trp-2₁₈₁₋₁₈₈ and OVA₂₅₇₋₂₆₄ were cloned as XbaI/BamHI fragments (see Fig. 1) with synthetic oligonucleotides, which were used for PCR amplification of the gene segments encoding m β ₂m leader peptide.

The sequence of the sense primer is:

5' GCG TCT AGA GCT TCA GTC GTC AGC ATG GCT CGC 3' (SEQ ID
20 NO: 54)

It comprises 3b protection, an XbaI site and positions 38-61 in GenBank accession X01838, composed of 15 b 5' non- translated region of m β ₂m leader and the first 3 leader codons, including the ATG.

The sense sequence of the reverse primer for TRP-2₁₈₁₋₁₈₈ is:

25 5' CTG ACC GGC TTG TAT GCT GTG TAT GAC TTT TTT GTG TGG CTC
GGA GGT GGC GGA TCC GCG 3' (SEQ ID NO: 55)

It corresponds to the last 6 codons of the m β ₂m leader, the 8 codons for TRP-2₁₈₁₋₁₈₈ (GBA X66349 945-968), the first 5 codons of the linker peptide and 3b protection.

30 The final (reverse complementary sequence) is:

5' CGC GGA TCC GCC ACC TCC GAG CCA CAC AAA AAA GTC ATA CAC
AGC ATA CAA GCC GGT CAG 3' (SEQ ID NO: 56)

The sense sequence of the reverse primer for OVA₂₅₇₋₂₆₄ is:

5' CTG ACC GGC TTG TAT GCT AGT ATA ATC AAC TTT GAA AAA CTG

5 GGA GGT GGC GGA TCC GCG 3' (SEQ ID NO: 57)

It corresponds to the last 6 codons of the m β_2 m leader, the 8 codons for the OVA₂₅₇₋₂₆₄ (GenBank accession J00895, positions 7870-7893), the first 5 codons of the linker peptide and 3b protection.

The final (reverse complementary) sequence is:

10 5' CGC GGA TCC GCC ACC TCC CAG TTT TTC AAA GTT GAT TAT ACT
AGC ATA CAA GCC GGT CAG 3' (SEQ ID NO: 58)

As a BamHI/XhoI fragment encoding the carboxyl terminal of the linker peptide, the full mature h β_2 m and the amino terminal of the bridge we used the same fragment described in WO 01/91698. We created a similar fragment encoding 15 m β_2 m, with the sequence of SEQ ID NO: 59:

gga tcc gga ggt ggt tct ggt gga ggt tcg atc cag aaa acc cct caa att caa gta tac
tca cgc cac cca ccg gag aat ggg aag ccg aac ata ctg aac tgc tac gta aca cag ttc cac
ccg cct cac att gaa atc caa atg ctg aag aac ggg aaa aaa att cct aaa gta gag atg tca gat
atg tcc ttc agc aag gac tgg tct ttc tat atc ctg gct cac act gaa ttc acc ccc act gag act gat
aca tac gcc tgc aga gtt aag cat gac agt atg gcc gag ccc aag acc gtc tac tgg gat cga gac
atg ctg aga tgg gag ccc *tcg* *agc*

20 From the 11th codon (atc) till the 8th codon before the end (atg) it encompasses positions 113-409 in GenBank accession X01838.

The sequence of the sense primer is:

25 5' GCG GGA TCC GGA GGT GGT TCT GGT GGA GGT TCG ATC CAG AAA
ACC CCT CAA ATT C 3' (SEQ ID NO: 60)

It comprises 3b protection, a BamHI site, a segment encoding the carboxyl terminal of the linker peptide and the first 7 codons of the mature m β_2 m.

The sequence of the reverse primer is:

5' GCG GCT CGA GGG CTC CCA TCT CAG CAT GTC TCG ATC CCA GTA
GAC 3' (SEQ ID NO: 61)

It comprises 4b protection, an XhoI site and it corresponds the last 7 codons of m β ₂m and to the amino terminal part of the bridge.

5 RT-PCR for amplification of m β ₂m sequences was performed on mRNA prepared from MD45 cells. Following verification of DNA sequences, each of the two XbaI/BamHI fragments was cloned into either pCI-Neo or pBJ1-Neo expression vectors, together with the BamHI/XhoI and the XhoI/NotI fragments described herein.

10 Stable transfectants with the resulting plasmids were generated and are listed in **Table 1**.

In order to evaluate expression of the new dc β ₂m constructs, we performed the FACS analysis shown in **Fig. 4**. In this experiment, we compared expression of different MHC class I components on RMA, RMA-S and Y317-2 cells (transfected 15 with OVA₂₅₇₋₂₆₄ fused to membranal h β ₂m), both at 37°C and 27°C. At this lower temperature MHC class I molecules on the TAP-deficient RMA-S cells are stabilized and their cell surface level increases. It is evident from this analysis that level of both H-2K^b and H-2D^b is considerably higher in Y317-2 cells than in their parental RMA-S cells. These results support our previous ones (**Fig. 3**) in showing 20 that the chimeric polypeptide can associate on the cell surface with allelic products (in this case H-2D^b) other than the one binding the encoded antigenic peptide (K^b). Surface expression of the antigenic K^b/OVA₂₅₇₋₂₆₄ complex (as judged by staining with the 25D-1.16 mAb) conclusively indicates that presentation is TAP-independent. Comparison of mean fluorescence intensity (MFI) of expression at 25 37°C is presented in **Table 3** and reveals 57% H-2K^b occupancy in the transfectant.

Table 3. Mean fluorescence intensities of clone Y317-2 stained with an allele-specific and complex-specific mAbs.

		<u>Antibody</u>
<u>Cell</u>	<u>Anti-H-2K^b</u>	<u>25D-1.16</u>
5	Y317-2	121.7 69.7

We then went on to confirm that the linker peptide, which joins the carboxyl terminal of the antigenic peptide to the amino terminal of β_2m , does not interfere with T cell recognition. To this end we examined specific activation of B3Z, an H-2K^b-restricted, OVA₂₅₇₋₂₆₄-specific CTL hybridoma, by RMA-S clones expressing dc β_2m with OVA₂₅₇₋₂₆₄. The results, presented in Fig. 5, show that the level of activation is indistinguishable from that achieved following incubation of parental RMA-S cells with synthetic OVA₂₅₇₋₂₆₄ and rule out major disruption of TCR-ligand interaction in this case.

Example 3. Evaluating contribution of membrane anchorage of β_2m to MHC class I stability

In the experimental system described in WO 01/91698, a plasmid was assembled, designated 21-2, which encodes a membranal h β_2m , linked to the transmembrane and cytoplasmic region of mouse CD3 ζ chain. Another plasmid, 323-3 was assembled, in which the CD3 ζ portion was replaced with those of H-2Kb. This was done as follows:

Scheme of genetic constructs encoding these single chimeric β_2m (sc β_2m) derivatives and of their expected polypeptide products associated with an MHC class I heavy chain are illustrated in Fig. 6.

Plasmid 21-2 was introduced into RMA-S cells. Following FACS analysis of G418-resistant transfectants with the anti-h β_2m antibody, two clones, designated KD21-4 and KD21-6, were chosen, the latter expressing higher level of membranal

5 β_2m . These two clones were analyzed for the ability of the $sc\beta_2m$ product to stabilize the MHC class I molecule H-2D^b at 37°C. Results of a typical experiment are presented in Fig. 7. It is clear from these results that H-2D^b level is elevated at 37°C compared with the parental RMA-S cells, and that this elevation correlates with expression level of $h\beta_2m$. In fact, for KD21-6, the level of surface H-2D^b is comparable to that of the wild-type RMA cells.

Plasmid 323-3 was similarly introduced to RMA-S cells and a stable transfectant, designated D323-4, which expresses high level of $h\beta_2m$, was selected. 10 In the next experiment we evaluated the ability of both KD21-6 and D323-4 transfectants to bind exogenously added synthetic OVA₂₅₇₋₂₆₄ peptide through H-2K^b, in comparison with parental RMA-S cells, exploiting the complex-specific 15 25D-1.16 mAb. This experiment was repeated 6 times, producing essentially identical results. Results of one of these experiments are shown in Fig. 8. They demonstrate approximately 3 logs enhancement of the ability to bind exogenous peptide, while maximal level of binding increases only 3-4-fold compared with RMA-S cells. These findings imply that expression of the $sc\beta_2m$ products results in a vast enhancement in the functional affinity of the antigenic peptide to the MHC 20 class I molecule. It should be noted that the nature of the β_2m anchor (CD3 ζ in KD21-6 or H-2K^b in D323-4) has little influence on the magnitude of this striking phenomenon.

Example 4. In-vivo assessment of $dc\beta_2m$ -based APCs

For in vivo evaluation of the capacity of $dc\beta_2m$ -based APCs to induce a specific CTL response, the RMA-S transfectants Y317-2 and Y314-7, expressing 25 OVA₂₅₇₋₂₆₄ linked to $h\beta_2m$ or $m\beta_2m$, respectively, were compared with cells exogenously loaded by peptides. In a preliminary experiment, C57BL/6 (B6) mice were immunized with the indicated cells. CTLs prepared from immunized mice were used in a cell cytotoxicity assay, in which transfectants were evaluated as target cells at various effector/target ratios. Results are depicted in Fig. 9 and 30 indicate that both Y317-2 and Y314-7 cells can serve as immunogens and as target

cells for CTLs. These finding reinforce our previous conclusion that dc β 2m is an efficient vehicle for presentation of pre-selected antigenic peptides and that the linker peptide does not interfere with T cell recognition.

5 **Example 5. Assembly and preliminary evaluation of β 2m fused to CD40 transmembrane and cytoplasmic region**

DC licensing requires engagement of the CD40L on the CD4 T cell with CD40 on the DC and is a mandatory step in the elicitation of many CTL responses. We reasoned that supplementing β 2m with the intracellular portion of CD40 might 10 trigger CD40 signaling upon encounter of DCs expressing these new dc β 2m constructs with specific CTLs, circumventing CD4 T cell help. In other words, the CD40 signaling moiety can serve as an adjuvant in membranal β 2m-based vaccines. To test this idea we assembled a new sc β 2m expression plasmid (encoding h β 2m, according to the general scheme illustrated in **Fig. 6**), in which the encoded anchor 15 comprises CD40 transmembrane and cytoplasmic portion. This was done as follows:

20 The bridge is LRWEPSSSTVSNM (SEQ ID NO:50), a fusion between the connecting peptide of H-K^b with that of HLA-A2, as in **Example 2**. The gene segment encoding mouse CD40 transmembrane and cytoplasmic region encompasses positions 588-878 in GenBank accession M83312 and its DNA sequence (SEQ ID NO: 62) is:

25
gcc ctg ctg gtc att cct gtc gtg atg ggc atc ctc atc acc att ttc ggg gtg ttt ctc tat
atc aaa aag gtg gtc aag aaa cca aag gat aat gag atg tta ccc cct gcg gct cga cgg caa gat
ccc cag gag atg gaa gat tat ccc ggt cat aac acc gct gct cca gtg cag gag aca ctg cac
ggg tgt cag cct gtc aca cag gag gat ggt aaa gag agt cgc atc tca gtg cag gag cgg cag
gtg aca gac agc ata gcc ttg agg ccc ctg gtc tga.

The sequence of the sense primer (SEQ ID NO: 63) is:

5' CCC TCG AGC TCC ACT GTC TCC AAC ATG GCC CTG CTG GTC
ATT CCT G 3'.

It comprises 2b protection, an XhoI site followed by the 3' part of the segment encoding the bridge and the first 19b encoding the CD40 portion.

The sequence of the reverse primer (SEQ ID NO: 64) is:

5' CGC GCG GCC GCG GTC AGC AAG CAG CCA TC 3'

5 It corresponds to a stretch downstream the CD40 stop codon (positions 901-918 in GenBank Accession M83312) and contains NotI and 3b protection.

Messenger RNA was prepared from the murine B cell lymphoma A20, known to express CD40, and RT-PCR was performed with the two primers. The 369 bp product was cloned into pGEMT and DNA sequence was confirmed. The 10 XhoI-NotI fragment was excised and inserted into the expression vector pBJ1-Neo cut with XbaI and NotI, together with the XbaI-XhoI fragment from plasmid 21-2, encoding h β ₂m with its leader peptide and the amino terminal of the bridge.

In order to assess function of the CD40 domains, we took advantage of the finding that CD40 can activate the nuclear factor of activated T cells (NFAT) (Choi et al., 1994). Plasmid DNA was introduced into B3Z cells (capable of high LacZ expression following stimulation through the NFAT-LacZ reporter gene) and resulting clones were screened for h β ₂m expression. FACS analysis, shown in Fig. 15 10, reveals high expression of h β ₂m in one of the transfectants (Y340-13) but none in the parental B3Z cells.

REFERENCES

Andersen, P. S., Stryhn, A., Hansen, B. E., Fugger, L., Engberg, J., and Buus, S. 1996. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. *Proc Natl Acad Sci U S A* 93:1820-4.

5 Armstrong, T. D., Pulaski, B. A., and Ostrand-Rosenberg, S. 1998. Tumor antigen presentation: changing the rules. *Cancer Immunol. Immunother.* 46:70-4.

Benton, P. A. and Kennedy, R. C. 1998. DNA vaccine strategies for the treatment of cancer. *Curr Top Microbiol Immunol* 226:1-20.

10 Berger, C. L., Longley, B. J., Imaeda, S., Christensen, I., Heald, P., and Edelson, R. L. 1998. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. *Int J Cancer* 76:304-11.

15 Bloom, M. B., Perry-Lalley, D., Robbins, P. F., Li, Y., el-Gamil, M., Rosenberg, S. A., and Yang, J. C. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. *J Exp Med* 185:453-9.

Bubenik, J. 2001. Genetically engineered dendritic cell-based cancer vaccines (review). *Int J Oncol.* 18:475-8.

20 Chen, W., Rains, N., Young, D., and Stubbs, R. S. 2000. Dendritic cell-based cancer immunotherapy: potential for treatment of colorectal cancer? *J Gastroenterol Hepatol* 15:698-705.

Choi, M. S., Brines, R. D., Holman, M. J., and Klaus, G. G. 1994. Induction of NFAT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with IL-4. *Immunity* 1:179-87.

25 Cohen, I. R. and Weiner, H. L. 1988. T-cell vaccination. *Immunol Today* 9:332-5.

Dalgleish, A. G. 2001. Current problems in the development of specific immunotherapeutic approaches to cancer. *J.Clin. Pathol.* 54:675-6.

Feldman M. and Eisenbach L. 1991. MHC class I genes controlling the metastatic phenotype of tumor cells. *Semin Cancer Biol.* Oct;2(5):337-46:

5 Gervois, N., Guilloux, Y., Diez, E., and Jotereau, F. 1996. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. *J. Exp. Med.* 183:2403-7.

Gilboa, E., Nair, S. K., and Lyerly, H. K. 1998. Immunotherapy of cancer with dendritic-cell-based vaccines. *Cancer Immunol, Immunother* 46:82-7.

10 Gilboa, E. 1999. The makings of a tumor rejection antigen. *Immunity* 11:263-70.

Gong, J., Chen, D., Kashiwaba, M., and Kufe, D. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. *Nature Medicine* 3:558-61.

15 Gong, J., Nikrui, N., Chen, D., Koido, S., Wu, Z., Tanaka, Y., Cannistra, S., Avigan, D., and Kufe, D. 2000. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. *J Immunol* 165:1705-11.

Guérmonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigorena, S. 20 2002. Antigen presentation and T cell stimulation by dendritic cells. *Annu Rev Immunol* 20:621-67.

Gurunathan, S., Klinman, D. M., and Seder, R. A. 2000. DNA vaccines: immunology, application, and optimization*. *Annu Rev Immunol* 18:927-74.

25 Hadzantonis, M. and O'Neill, H. 1999. Review: dendritic cell immunotherapy for melanoma. *Cancer Biother Radiopharm.* 14:11-22.

Heath, W. R. and Carbone, F. R. 2001. Cross-presentation, dendritic cells, tolerance and immunity. *Annual Review of Immunology* 19:47-64.

5 Horig, H., Young, A. C., Papadopoulos, N. J., DiLorenzo, T. P., and Nathenson, S. G. 1999. Binding of longer peptides to the H-2K^b heterodimer is restricted to peptides extended at their C terminus: refinement of the inherent MHC class I peptide binding criteria. *J Immunol* 163:4434-41.

Jager, E., Jager, D., and Knuth, A. 2002. Clinical cancer vaccine trials. *Curr Opin Immunol* 14:178-82.

10 Janeway, C. A. and Bottomly, K. 1994. Signals and signs for lymphocyte responses. *Cell* 76:275-85.

Kaufmann, Y., Berke, G., and Eshhar, Z. 1981. Cytotoxic T lymphocyte hybridomas that mediate specific tumor-cell lysis in vitro. *Proc Natl Acad Sci U S A* 78:2502-6.

15 Kumar, V., Tabibiazar, R., Geysen, H. M., and Sercarz, E. 1995. Immunodominant framework region 3 peptide from TCR V beta 8.2 chain controls murine experimental autoimmune encephalomyelitis. *J Immunol* 154:1941-50.

Kumar, V. and Sercarz, E. 2001. An integrative model of regulation centered on recognition of TCR peptide/MHC complexes. *Immunol Rev* 182:113-21.

20 Levitsky, V., Zhang, Q. J., Levitskaya, J., and Masucci, M. G. 1996. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. *Jf Exp Med* 183:915-26.

25 Lone, Y. C., Motta, I., Mottez, E., Guilloux, Y., Lim, A., Demay, F., Levraud, J. P., Kourilsky, P., and Abastado, J. P. 1998. In vitro induction of specific

cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes. *J Immunother* 21:283-94.

Minev, B. R., Chavez, F. L., and Mitchell, M. S. 1999. Cancer vaccines: novel approaches and new promise. *Pharmacol and Therapeut* 81:121-39.

5 Moingeon, P. 2001. Cancer vaccines. *Vaccine* 19:1305-26.

Mottez, E., Langlade-Demoyen, P., Gournier, H., Martinon, F., Maryanski, J., Kourilsky, P., and Abastado, J. P. 1995. Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic. *J Exp Med* 181:493-502.

10 Nouri-Shirazi, M., Banchereau, J., Fay, J., and Palucka, K. 2000. Dendritic cell based tumor vaccines. *Immunol Letters* 74:5-10.

15 Offner, H., Jacobs, R., Bebo, B. F., Jr., and Vandenbark, A. A. 1999. Treatments targeting the T cell receptor (TCR): effects of TCR peptide- specific T cells on activation, migration, and encephalitogenicity of myelin basic protein- specific T cells. *Springer Semin Immunopathol* 21:77-90.

Ojcius, D. M., Langlade-Demoyen, P., Gachelin, G., and Kourilsky, P. 1994. Role for MHC class I molecules in selecting and protecting high affinity peptides in the presence of proteases. *J Immunol* 152:2798-810.

20 Porgador, A., Snyder, D., and Gilboa, E. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. *J Immunol* 156:2918-26.

Porgador, A., Feldman, M., and Eisenbach, L. 1989. H-2K^b transfection of B16 melanoma cells results in reduced tumourigenicity and metastatic competence. *J Immunogen* 16:291-303.

Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R., and Germain, R. N. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. *Immunity* 6:715-26.

5 Porgador, A., Irvine, K. R., Iwasaki, A., Barber, B. H., Restifo, N. P., and Germain, R. N. 1998. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. *J Exp Med* 188:1075-82.

Reis e Sousa, C. 2001. Dendritic cells as sensors of infection. *Immunity* 14:495-8.

10 Rosenberg, S. A. 1999. A new era of cancer immunotherapy: converting theory to performance. *CA Cancer J Clin.* 49:70-3, 65.

Sanderson, S. and Shastri, N. 1994. LacZ inducible, antigen/MHC-specific T cell hybrids. *Int Immunol* 6:369-76.

15 Saric, T., Chang, S. C., Hattori, A., York, I. A., Markant, S., Rock, K. L., Tsujimoto, M., and Goldberg, A. L. 2002. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. *Nat Immunol* 3:1169-76.

Serwold, T., Gonzalez, F., Kim, J., Jacob, R., and Shastri, N. 2002. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. 20 *Nature* 419:480-3.

Sherritt, M., Cooper, L., Moss, D. J., Kienzle, N., Altman, J., and Khanna, R. 2001. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters. *Int Immunol* 13:265-71.

Snyder, H. L., Yewdell, J. W., and Bennink, J. R. 1994. Trimming of antigenic peptides in an early secretory compartment. *J Exp Med* 180:2389-94.

5 Snyder, H. L., Bacik, I., Yewdell, J. W., Behrens, T. W., and Bennink, J. R. 1998. Promiscuous liberation of MHC-class I-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway. *Eur J Immunol* 28:1339-46.

Sogn, J. A. 1998. Tumor immunology: the glass is half full. *Immunity* 9:757-63.

10 Sogn, J. A. 2000. The status of tumor immunology and cancer immunotherapy. Introduction. *Immunol Investig* 29:81-4.

Steinman, R. M. 1989. Dendritic cells: clinical aspects. *Res Immunol* 140:911-8; discussion 918-26.

15 Stryhn, A., Pedersen, L. O., Holm, A., and Buus, S. 2000. Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism. *Eur J Immunol* 30:3089-99.

Tafuro, S., Meier, U. C., Dunbar, P. R., Jones, E. Y., Layton, G. T., Hunter, M. G., Belli, J. I., and McMichael, A. J. 2001. Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2m fusion molecules. *Eur J Immunol* 31:440-9.

20 Takahashi, H., Nakagawa, Y., Yokomuro, K., and Berzofsky, J. A. 1993. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. *Int Immunol* 5:849-57.

25 Tirosh, B., el_Shami, K., Vaisman, N., Carmon, L., Bar_Haim, E., Vadai, E., Feldman, M., Fridkin, M., and Eisenbach, L. 1999. Immunogenicity of H-2Kb-low

affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination.
Immunol Letters 70:21-8.

5 Tsomides, T. J., Aldovini, A., Johnson, R. P., Walker, B. D., Young, R. A., and Eisen, H. N. 1994. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. *J Exp Med* 180:1283-93.

Uger, R. A. and Barber, B. H. 1998. Creating CTL targets with epitope-linked beta 2-microglobulin constructs. *J Immunol* 160:1598-605.

10 Uger, R. A., Chan, S. M., and Barber, B. H. 1999. Covalent linkage to beta2-microglobulin enhances the MHC stability and antigenicity of suboptimal CTL epitopes. *J Immunol* 162:6024-8.

Vora, A. R., Rodgers, S., Parker, A. J., Start, R., Rees, R. C., and Murray, A. K. 1997. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. *Brit J Cancer* 76:836-44.

15 Watson, G. A. and Lopez, D. M. 1995. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. *J Immunol* 155:3124-34.

20 Wen, Y. J. and Lim, S. H. 1997. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. *Eur J Immunol* 27:1043-7.

White, J., Crawford, F., Fremont, D., Marrack, P., and Kappler, J. 1999. Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma. *J Immunol* 162:2671-6.

25 York, I. A., Chang, S. C., Saric, T., Keys, J. A., Favreau, J. M., Goldberg, A. L., and Rock, K. L. 2002. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. *Nat Immunol* 3:1177-84.

Zhang, W., Cao, X., and Huang, X. 1997. [In vivo induction of antitumor immune response by tumor cells fused with GM-CSF gene-modified dendritic cells]. *Zhonghua Yi Xue Za Zhi. (Chinese)*. 77:39-42.

CLAIMS:

1. A polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a β_2 -microglobulin molecule that is linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β_2 -microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope, wherein said antigenic peptide is not related to an autoimmune disease.
- 10 2. The polynucleotide of claim 1, wherein said polypeptide stretch at the β_2 -microglobulin carboxyl terminal consists of a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a sequence which can exert the required anchoring function.
- 15 3. The polynucleotide of claim 2, wherein said bridge peptide is the peptide of SEQ ID NO: 1, of the sequence: LRWEPESSQPTIPI.
- 20 4. The polynucleotide of claim 2 or 3, wherein said bridge peptide is linked to the full or partial transmembrane and/or cytoplasmic domain of a molecule selected from the group consisting of: (i) a human MHC class I molecule selected from an HLA-A, HLA-B or HLA-C molecule; (ii) a costimulatory B7.1, B7.2 OR CD40 molecule; and (iii) a signal transduction element capable of activating T cells or antigen-presenting cells.
- 25 5. The polynucleotide of claim 4, wherein said bridge peptide is linked to the transmembrane and cytoplasmic domains from the MHC class I heavy chain HLA-A2 molecule, of the SEQ ID NO: 2, of the sequence:

VGIIAGLVLFGAVITGAVVAAVMWRRKSSDRKGGSYSQAASSDSAQ
GSDVSLTACKV

6. The polynucleotide of claim 4 wherein said transduction element capable of activating T cells is selected from the group consisting of a component of T-cell receptor CD3, a B cell receptor polypeptide, and an Fc receptor polypeptide.

5 7. The polynucleotide of claim 6, wherein said component of T-cell receptor CD3 is the zeta (ζ) or eta (η) polypeptide.

8. The polynucleotide of claim 6, wherein said component of T-cell receptor CD3 comprises the transmembranal and cytoplasmic regions of the human CD3 ζ 10 polypeptide.

9. The polynucleotide of claim 2 or 3, wherein said bridge peptide is linked through its carboxyl terminal to a GPI-anchor sequence.

15 10. The polynucleotide of claim 9, wherein said GPI-anchor is a peptide of SEQ ID NO: 3, of the sequence: FTLTGLLGTLVTMGLLT.

11. The polynucleotide of any one of claims 1 to 10, wherein said at least one antigenic peptide comprising a MHC class I epitope is linked to the β_2 - 20 microglobulin amino terminal through a peptide linker.

12. The polynucleotide of claim 1, wherein said at least one antigenic peptide is at least one antigenic determinant of one sole antigen.

25 13. The polynucleotide of claim 11, wherein said at least one antigenic peptide is at least one antigenic determinant of each one of at least two different antigens.

14. The polynucleotide of claim 12 or 13, wherein said antigen is a tumor-associated antigen (TAA).

15. The polynucleotide of claim 14, wherein said TAA is selected from the group consisting of alpha-fetoprotein, BA-46/lactadherin, BAGE, BCR-ABL fusion protein, beta-catenin, CASP-8, CDK4, CEA, CRIPTO-1, elongation factor 2, ETV6-AML1 fusion protein, G250, GAGE, gp100, HER-2/neu, intestinal carboxyl esterase, KIAA0205, MAGE, MART-1/Melan-A, MUC-1, N-ras, p53, PAP, PSA, PSMA, telomerase, TRP-1/gp75, TRP-2, tyrosinase, and uroplakin Ia, Ib, II and III.

16. The polynucleotide of claim 15, wherein said antigenic peptide is selected from the group consisting of:

10 (i) the alpha-fetoprotein peptide GVALQTMKQ (SEQ ID NO:4);
(ii) the BAGE-1 peptide AARAVFLAL (SEQ ID NO:5);
(iii) the BCR-ABL fusion protein peptide SSKALQRPV (SEQ ID NO:6);
(iv) the beta-catenin peptide SYLDSGIHF (SEQ ID NO:7);
(v) the CDK4 peptide ACDPHSGHFV (SEQ ID NO:8);
15 (vi) the CEA peptide YLSGANLNL (SEQ ID NO:9);
(vii) the elongation factor 2 peptide ETVSEQSNV (SEQ ID NO:10);
(viii) the ETV6-AML1 fusion protein peptide RIAECILGM (SEQ ID NO:11);
20 (ix) the G250 peptide HLSTAFARV (SEQ ID NO:12);
(x) the GAGE-1,2,8 peptide YRPRPRRY (SEQ ID NO:13);
(xi) the gp100 peptides KTWGQYWQV (SEQ ID NO:14),
25 (A)MLGTHTMEV (SEQ ID NO:15), ITDQVPFSV (SEQ ID NO:16), YLEPGPVTA (SEQ ID NO:17), LLDGTATLRL (SEQ ID NO:18),
VLYRYGSFSV (SEQ ID NO:19), SLADTNSLAV (SEQ ID NO:20),
RLMKQDFSV (SEQ ID NO:21), RLPRIFCSC (SEQ ID NO:22),
LIYRRRLMK (SEQ ID NO:23), ALLAVGATK (SEQ ID NO:24),
IALNFPGSQK (SEQ ID NO:25) and ALNFPGSQK (SEQ ID NO:26);
30 (xii) the HER-2/neu peptide KIFGSLAFL (SEQ ID NO:27);
(xiii) the intestinal carboxyl esterase peptide SPRWWPTCL (SEQ ID NO:28);

(xiv) the KIAA0205 peptide AEPINIQTW (SEQ ID NO:29);
(xv) the MAGE-1 peptides EADPTGHSY (SEQ ID NO:30) and SLFRAVITK (SEQ ID NO:31);
(xvi) the MAGE-3 peptides EVDPIGHLY (SEQ ID NO:32) and FLWGPRALV (SEQ ID NO:33);
5 (xvii) the MART-1/Melan-A peptide (E)AAGIGILTV (SEQ ID NO:34);
(xviii) the MUC-1 peptide STAPPVHNV (SEQ ID NO:35);
(xix) the N-ras peptide ILDTAGREEY (SEQ ID NO:36);
(xx) the p53 peptide LLGRNSFEV (SEQ ID NO:37);
10 (xxi) the PSA peptides FLTPKKLQCV (SEQ ID NO:38) and VISNDVCAQV (SEQ ID NO:39);
(xxii) the telomerase peptide ILAKFLHWL (SEQ ID NO:40);
(xxiii) the TRP-1 peptide MSLQRQFLR (SEQ ID NO:41);
15 (xxiv) the TRP-2 peptides LLGPGRPYR (SEQ ID NO:42), SVYDFFVWL (SEQ ID NO:43), and TLDSQVMSL (SEQ ID NO:44);
(xxv) the TRP2-INT2 peptide EVISCKLIKR (SEQ ID NO:45); and
(xxvi) the tyrosinase peptide KCDICTDEY (SEQ ID NO:46).

17. The polynucleotide of any one of claims 14 to 16, wherein said at least one
20 antigenic peptide is at least one antigenic determinant of one sole tumor-associated
antigen.

18. The polynucleotide of claim 17, wherein said at least one antigenic peptide
is at least one HLA-A2 binding peptide and at least one HLA-A3 binding peptide
25 derived from the melanoma-associated antigen gp100.

19. The polynucleotide of claim 18, wherein said at least one HLA-A2 binding
peptide derived from gp100 is selected from the group consisting of SEQ ID NO:
30 14, 15, 16, 17, 18, 19, 20, 21 and 22, and said at least one gp100 HLA-A3 binding
peptide is selected from the group consisting of SEQ ID NO: 23, 24, 25 and 26.

20. The polynucleotide of any one of claims 14 to 16, wherein said at least one antigenic peptide is at least one antigenic determinant of each one of at least two different tumor-associated antigens.

5 21. The polynucleotide of claim 20, wherein said at least one antigenic peptide is at least one HLA-A2 binding peptide derived from each one of the melanoma associated antigens gp100 and Melan-A/MART-1.

10 22. The polynucleotide of claim 21, wherein said at least one antigenic peptide is at least one HLA-A3-restricted gp100 and at least one HLA-A2-restricted Melan-A/MART-1 peptide.

15 23. The polynucleotide of claim 12 or 13, wherein said antigen is an antigen from a pathogen selected from the group consisting of a bacterial, viral, fungal and parasite antigen.

24. The polynucleotide of claim 23 wherein the antigen is a viral antigen.

20 25. The polynucleotide of claim 24 wherein the viral antigen is an HIV protein selected from the group consisting of the HIV-1 regulatory proteins Tat and Rev and the HIV envelope protein, in which case the antigenic peptide derived therefrom has the sequence RGPGRGAFVTI (SEQ ID NO:47).

25 26. The polynucleotide of claim 11, wherein said at least one antigenic peptide is at least one idiotypic peptide expressed by autoreactive T lymphocytes.

30 27. The polynucleotide of claim 26, wherein said at least one idiotypic peptide is derived from a CDR (complementarity-determining region) sequence of an immunoglobulin or of a TCR chain, optionally containing said CDR flanking segments.

28. The polynucleotide of claim 27, wherein said CDR is the CDR3 of an immunoglobulin or of a TCR chain.

5 29. The polynucleotide of any one of claims 1 to 28 that is an expression vector.

30. An expression vector comprising a polynucleotide according to any one of claims 1 to 28.

10 31. A recombinant viral vector of claim 30.

32. An antigen-presenting cell transfected with a polynucleotide comprising a sequence encoding a polypeptide comprising a β_2 -microglobulin molecule that is linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β_2 -microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope.

15

33. The antigen-presenting cell of claim 32 selected from the group consisting of a dendritic cell, a macrophage, a B cell and a fibroblast.

20 34. The antigen-presenting cell of claim 32 or 33 wherein said antigenic peptide is a peptide not related to an autoimmune disease.

35. The antigen-presenting cell of claim 34, wherein said antigenic peptide is at least one peptide derived from at least one TAA.

25 36. The antigen-presenting cell of claim 34, wherein said antigenic peptide is at least one peptide derived from an antigen from a pathogen selected from the group consisting of a bacterial, a viral, a fungal and a parasite antigen.

37. A DNA vaccine comprising a polynucleotide of any one of claims 1 to 28 or an expression vector of claim 30 or 31.

38. The DNA vaccine of claim 37 for prevention or treatment of cancer wherein 5 said polynucleotide is a polynucleotide of any one of claims 14 to 22.

39. The DNA vaccine of claim 37 for prevention or treatment of a disease caused by a pathogenic organism wherein said polynucleotide is a polynucleotide of any one of claims 23 to 25.

10

40. A cellular vaccine, which comprises an antigen presenting cell of claim 32.

41. The cellular vaccine of claim 39 wherein the antigen presenting cell is selected from the group consisting of a dendritic cell, a macrophage, a B cell and a 15 fibroblast.

42. The cellular vaccine of claim 41, wherein the at least one antigenic peptide presented by the antigen presenting cell is a peptide not related to an autoimmune disease.

43. The cellular vaccine of claim 42 for prevention or treatment of cancer 20 wherein the antigen presenting cell presents at least one peptide derived from at least one tumor associated antigen.

44. The cellular vaccine of claim 42 for prevention or treatment of a disease caused by a pathogenic organism wherein the antigen presenting cell presents at least one peptide derived from a pathogenic antigen.

25 45. A cellular vaccine for the prevention or treatment of cancer comprising antigen presenting cells which express a polypeptide consisting of β_2 -microglobulin linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β_2 -microglobulin molecule to a cell membrane, wherein said cells

have been pulsed with at least one antigenic peptide derived from at least one tumor associated antigen.

46. A cellular vaccine for treatment of cancer comprising tumor cells transfected with a polynucleotide comprising a sequence encoding a polypeptide comprising a β_2 -microglobulin molecule that is linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the β_2 -microglobulin molecule to the cell membrane.

47. A method of immunizing a mammal against a tumor-associated antigen comprising the step of immunizing the mammal with a cellular vaccine of any one of claims 43, 45 or 46.

48. A method of immunizing a mammal against a disease caused by a pathogenic organism comprising the step of immunizing the mammal with a cellular vaccine of claim 44.

15 49. A pharmaceutical composition comprising as an active ingredient at least one polynucleotide of any one of claims 1 to 29 or an expression vector of claim 30 or 31, and a pharmaceutically acceptable carrier.

20 50. The pharmaceutical composition of claim 49 wherein the polynucleotide comprises a sequence encoding a polypeptide comprising at least one antigenic peptide derived from at least one tumor associated antigen.

51. The pharmaceutical composition of claim 49 wherein the polynucleotide comprises a sequence encoding a polypeptide comprising at least one antigenic peptide derived from a pathogenic antigen.

25 52. A pharmaceutical composition comprising as an active ingredient at least one antigen presenting cell of any one of claims 32 to 36, and a pharmaceutically acceptable carrier.




Fig. 1A




Fig. 1B




Fig. 2A

427-24 (Ha) cells




Fig. 2 B















Fig. 2C

no Ab



Anti-TCR

Anti-K^dAnti-K^k

425-44

427-24

829S-36

Fig. 3




Fig. 4A

7/14




Fig. 4B

Y317-2 cells




Fig. 4C

B3Z




Fig. 5A

B3Z + anti-TCR




Fig. 5B

B3Z + RMA




Fig. 5C

B3Z + RMA+peptide




Fig. 5D

B3Z + Y318-7




Fig. 5E

B3Z + Y317-2




Fig. 5F




Fig. 5G






Fig. 6






Fig. 8




Fig. 9

Targets

Y314-7

Y317-2

RMA-S




Fig. 10

SEQUENCE LISTING

1/11

<110> GAVISH-GALILEE BIO APPLICATIONS LTD.
GROSS, Gideon
MARGALIT, Alon

<120> MEMBRANE-ANCHORED β 2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I
EPITOPES

<130> GAVISH-004 PCT

<150> US 60/388,273

<151> 2002-06-12

<160> 64

<170> PatentIn version 3.1

<210> 1

<211> 13

<212> PRT

<213> Synthetic sequence

<400> 1

Leu Arg Trp Glu Pro Ser Ser Gln Pro Thr Ile Pro Ile
1 5 10

<210> 2

<211> 57

<212> PRT

<213> Synthetic sequence

<400> 2

Val Gly Ile Ile Ala Gly Leu Val Leu Phe Gly Ala Val Ile Thr Gly
1 5 10 15

Ala Val Val Ala Ala Val Met Trp Arg Arg Lys Ser Ser Asp Arg Lys
20 25 30

Gly Gly Ser Tyr Ser Gln Ala Ala Ser Ser Asp Ser Ala Gln Gly Ser
35 40 45

Asp Val Ser Leu Thr Ala Cys Lys Val
50 55

<210> 3

<211> 17

<212> PRT

<213> Synthetic sequence

<400> 3

Phe Thr Leu Thr Gly Leu Leu Gly Thr Leu Val Thr Met Gly Leu Leu
1 5 10 15

Thr

<210> 4

<211> 9
<212> PRT
<213> Synthetic sequence

<400> 4

Gly Val Ala Leu Gln Thr Met Lys Gln
1 5

<210> 5
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 5

Ala Ala Arg Ala Val Phe Leu Ala Leu
1 5

<210> 6
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 6

Ser Ser Lys Ala Leu Gln Arg Pro Val
1 5

<210> 7
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 7

Ser Tyr Leu Asp Ser Gly Ile His Phe
1 5

<210> 8
<211> 10
<212> PRT
<213> Synthetic sequence

<400> 8

Ala Cys Asp Pro His Ser Gly His Phe Val
1 5 10

<210> 9
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 9

Tyr Leu Ser Gly Ala Asn Leu Asn Leu
1 5

<210> 10
<211> 9

<212> PRT
<213> Synthetic sequence

<400> 10

Glu Thr Val Ser Glu Gln Ser Asn Val
1 5

<210> 11
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 11

Arg Ile Ala Glu Cys Ile Leu Gly Met
1 5

<210> 12
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 12

His Leu Ser Thr Ala Phe Ala Arg Val
1 5

<210> 13
<211> 8
<212> PRT
<213> Synthetic sequence

<400> 13

Tyr Arg Pro Arg Pro Arg Arg Tyr
1 5

<210> 14
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 14

Lys Thr Trp Gly Gln Tyr Trp Gln Val
1 5

<210> 15
<211> 9
<212> PRT
<213> Artificial sequence

<220>
<223> The residue in position 1 is Met or Ala

<400> 15

Met Leu Gly Thr His Thr Met Glu Val
1 5

<210> 16
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 16

Ile Thr Asp Gln Val Pro Phe Ser Val
1 5

<210> 17
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 17

Tyr Leu Glu Pro Gly Pro Val Thr Ala
1 5

<210> 18
<211> 10
<212> PRT
<213> Synthetic sequence

<400> 18

Leu Leu Asp Gly Thr Ala Thr Leu Arg Leu
1 5 10

<210> 19
<211> 10
<212> PRT
<213> Synthetic sequence

<400> 19

Val Leu Tyr Arg Tyr Gly Ser Phe Ser Val
1 5 10

<210> 20
<211> 10
<212> PRT
<213> Synthetic sequence

<400> 20

Ser Leu Ala Asp Thr Asn Ser Leu Ala Val
1 5 10

<210> 21
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 21

Arg Leu Met Lys Gln Asp Phe Ser Val
1 5

<210> 22

<211> 9
<212> PRT
<213> Synthetic sequence

<400> 22

Arg Leu Pro Arg Ile Phe Cys Ser Cys
1 5

<210> 23
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 23

Leu Ile Tyr Arg Arg Arg Leu Met Lys
1 5

<210> 24
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 24

Ala Leu Leu Ala Val Gly Ala Thr Lys
1 5

<210> 25
<211> 10
<212> PRT
<213> Synthetic sequence

<400> 25

Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys
1 5 10

<210> 26
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 26

Ala Leu Asn Phe Pro Gly Ser Gln Lys
1 5

<210> 27
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 27

Lys Ile Phe Gly Ser Leu Ala Phe Leu
1 5

<210> 28
<211> 9

<212> PRT

<213> Synthetic sequence

<400> 28

Ser Pro Arg Trp Trp Pro Thr Cys Leu
1 5

<210> 29

<211> 9

<212> PRT

<213> Synthetic sequence

<400> 29

Ala Glu Pro Ile Asn Ile Gln Thr Trp
1 5

<210> 30

<211> 9

<212> PRT

<213> Synthetic sequence

<400> 30

Glu Ala Asp Pro Thr Gly His Ser Tyr
1 5

<210> 31

<211> 9

<212> PRT

<213> Synthetic sequence

<400> 31

Ser Leu Phe Arg Ala Val Ile Thr Lys
1 5

<210> 32

<211> 9

<212> PRT

<213> Synthetic sequence

<400> 32

Glu Val Asp Pro Ile Gly His Leu Tyr
1 5

<210> 33

<211> 9

<212> PRT

<213> Synthetic sequence

<400> 33

Phe Leu Trp Gly Pro Arg Ala Leu Val
1 5

<210> 34

<211> 9

<212> PRT

WO 03/106616

PCT/IL03/00501

<213> Artificial sequence

7/11

<220>

<223> The residue in position 1 is Ala or Glu

<400> 34

Ala Ala Gly Ile Gly Ile Leu Thr Val
1 5

<210> 35

<211> 9

<212> PRT

<213> Synthetic sequence

<400> 35

Ser Thr Ala Pro Pro Val His Asn Val
1 5

<210> 36

<211> 10

<212> PRT

<213> Synthetic sequence

<400> 36

Ile Leu Asp Thr Ala Gly Arg Glu Glu Tyr
1 5 10

<210> 37

<211> 9

<212> PRT

<213> Synthetic sequence

<400> 37

Leu Leu Gly Arg Asn Ser Phe Glu Val
1 5

<210> 38

<211> 10

<212> PRT

<213> Synthetic sequence

<400> 38

Phe Leu Thr Pro Lys Lys Leu Gln Cys Val
1 5 10

<210> 39

<211> 10

<212> PRT

<213> Synthetic sequence

<400> 39

Val Ile Ser Asn Asp Val Cys Ala Gln Val
1 5 10

<210> 40

<211> 9
<212> PRT
<213> Synthetic sequence

<400> 40

Ile Leu Ala Lys Phe Leu His Trp Leu
1 5

<210> 41
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 41

Met Ser Leu Gln Arg Gln Phe Leu Arg
1 5

<210> 42
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 42

Leu Leu Gly Pro Gly Arg Pro Tyr Arg
1 5

<210> 43
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 43

Ser Val Tyr Asp Phe Phe Val Trp Leu
1 5

<210> 44
<211> 9
<212> PRT
<213> Synthetic sequence

<400> 44

Thr Leu Asp Ser Gln Val Met Ser Leu
1 5

<210> 45
<211> 10
<212> PRT
<213> Synthetic sequence

<400> 45

Glu Val Ile Ser Cys Lys Leu Ile Lys Arg
1 5 10

<210> 46
<211> 9

<212> PRT
<213> Synthetic sequence

<400> 46

Lys Cys Asp Ile Cys Thr Asp Glu Tyr
1 5

<210> 47
<211> 10
<212> PRT
<213> Synthetic sequence

<400> 47

Arg Gly Pro Gly Arg Ala Phe Val Thr Ile
1 5 10

<210> 48
<211> 8
<212> PRT
<213> Synthetic sequence

<400> 48

Ser Ile Ile Asn Phe Glu Lys Leu
1 5

<210> 49
<211> 225
<212> DNA
<213> Synthetic sequence

<400> 49

gagccctcga gctccactgt ctccaaacatg gcgaccgttg ctgttctgggt tgccttggga 60

gctgcaatag tcactggagc tgtggtggt tttgtatga agatgagaag gagaaacaca 120

ggtgaaaaag gaggggacta tgctctggct ccaggctccc agacctctga tctgtctctc 180

ccagatttta aagtgtatggt tcatgaccct cattctcttag cgtga 225

<210> 50
<211> 13
<212> PRT
<213> Synthetic sequence

<400> 50

Leu Arg Trp Glu Pro Ser Ser Ser Thr Val Ser Asn Met
1 5 10

<210> 51
<211> 39
<212> DNA
<213> Synthetic sequence

<400> 51

ctgagatggg agccctcgag ctccactgtc tccaaacatg 39

<210> 52

<211> 30
<212> DNA
<213> Synthetic sequence

<400> 52
ccctcgagct ccactgtctc caacatggcg 30

<210> 53
<211> 29
<212> DNA
<213> Synthetic sequence

<400> 53
cgcgccggccg caagtccact ccaggcagc 29

<210> 54
<211> 33
<212> DNA
<213> Synthetic sequence

<400> 54
gcgtctagag cttagtcgt cagcatggct cgc 33

<210> 55
<211> 60
<212> DNA
<213> Synthetic sequence

<400> 55
ctgaccggct tgtatgctgt gtatgacttt tttgtgtggc tcggaggtgg cggatccg 60

<210> 56
<211> 60
<212> DNA
<213> Synthetic sequence

<400> 56
cgccgatccg ccacctccga gccacacaaa aaagtcatac acagcataca agccggtcag 60

<210> 57
<211> 60
<212> DNA
<213> Synthetic sequence

<400> 57
ctgaccggct tgtatgctag tataatcaac tttaaaaac tgggaggtgg cggatccg 60

<210> 58
<211> 60
<212> DNA
<213> Synthetic sequence

<400> 58
cgccgatccg ccacctccca gttttcaaa gttgattata ctagcataca agccggtcag 60

<210> 59
<211> 348
<212> DNA
<213> Synthetic sequence

11/11

<400> 59	ggatccggag gtggttctgg tggagggtcg atccagaaaa cccctcaa at tcaagtatac	60
	tcacgccacc caccggagaa tggaaagccg aacatactga actgctacgt aacacagttc	120
	cacccgcctc acattgaa at ccaa atgctg aagaacggga aaaaattcc taaa agt tagag	180
	atgtcagata tgccttcag caaggactgg tcttctata tcctggctca cactgaattc	240
	accccccactg agactgatac atacgcctgc agagttaagc atgacagtat ggccgagccc	300
	aagaccgtct actgggatcg agacatgctg agatgggagc cctcgagc	348

<210> 60		
<211> 55		
<212> DNA		
<213> Synthetic sequence		
<400> 60	gcgggatccg gaggtgggtc tggtgaggt tcgatccaga aaaccctca aattc	55

<210> 61		
<211> 45		
<212> DNA		
<213> Synthetic sequence		
<400> 61	gcggctcgag ggctccatc tcagcatgtc tcgatcccag tagac	45

<210> 62		
<211> 291		
<212> DNA		
<213> Synthetic sequence		
<400> 62	gcctgtgg tcattcctgt cgtatgggc atcctcatca ccatttcgg ggtgttctc	60
	tatataaaaa aggtggtcaa gaaaccaaag gataatgaga ttttacccccc tgccgctcga	120
	cgcaagatc cccaggagat ggaagattat cccggtcata acaccgctgc tccagtgcag	180
	gagacactgc acgggtgtca gcctgtcaca caggaggatg gttaaagagag tcgcatactca	240
	gtgcaggagc ggcagggtgac agacagcata gccttgaggc ccctggctcg a	291

<210> 63		
<211> 46		
<212> DNA		
<213> Synthetic sequence		
<400> 63	ccctcgagct ccactgtctc caacatggcc ctgctggtca ttccctg	46

<210> 64		
<211> 29		
<212> DNA		
<213> Synthetic sequence		
<400> 64	cgcgcggccg cggtcagcaa gcagccatc	29

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.